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SUMMARY 
 
Cyclic dipeptides (CDPs) are amino acid-based compounds, some of which possess 
antibacterial activity. The encapsulation of certain drugs into liposomes has been 
found to improve their activity in terms of bioavailability and duration of action.  
Liposomes are small vesicles that are under investigation as drug carriers for the 
delivery of therapeutic agents. A number of liposome formulations are currently 
under clinical trial review, whilst some have already been approved for clinical use.  
The aim of this study was to optimize a liposomal cyclo(Tyr-Pro) formulation and to 
assess its antibacterial activity against various Gram-positive  and Gram-negative 
bacteria.   
Response surface methodology (RSM) using the central composite design (CCD) 
model was used to optimize liposomal formulations of cyclo(Tyr-Pro) for each of the 
four bacteria, namely Bacillus cereus, Staphylococcus aureus, Escherichia coli and 
Pseudomonas aeruginosa. Percent drug encapsulated and bacterial inhibition were 
investigated with respect to two independent variables, i.e. lipid composition and 
cholesterol content. Design Expert 8 was used for the purpose of finding the 
combination of independent variables that would yield an optimal formulation for 
each bacterium.  The model selected by the software failed to adequately correlate 
the predicted models to the experimental data.   
The in vitro experiments showed that the antibacterial activity of liposome-
encapsulated cyclo(Tyr-Pro) was superior to that of its free counterpart. Binding 
maximum or Bmax for the encapsulated compound at concentrations as low as 0.412 
mg/ml, was significantly higher than that obtained for free cyclo(Tyr-Pro) which was 
tested at a concentration of 20 mg/ml. Furthermore, encapsulation of cyclo(Tyr-Pro) 
into a liposome formulation enhanced its potency.  This was evident in the lower IC50 
values for the liposomal compound when compared to free cyclo(Tyr-Pro) 
 
Key words: Cyclic dipeptides, liposomes, cyclo(Tyr-Pro), antibacterial activity, RSM, 
CCD
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background to study 
 
More than half a century ago, the golden era of antibiotics dawned, with important 
achievements in the discovery of sulphonamides, penicillin and streptomycin. This 
was followed by the development of tetracyclines, macrolides, glycopeptides, 
cephalosporins and nalidixic acid (Walsh 2003; Overbye and Barrett, 2005).  The era 
of the ‗conventional antibiotic‘ may be coming to a close, bacterial resistance has 
seen to that (Hancock, 1997).  Antibacterial resistance amongst pathogens 
continues to develop and spread globally, both in the hospital and community 
settings (Pavia, 1999). The emergence of resistance has been fuelled by the 
inevitable and natural process of genetic modification.  Short generation times for 
bacteria ensure relentless adaptation and the genetic strategies that have been 
adopted by bacteria are ingenious as well as diverse (Lipsitch, 2001).   
Notwithstanding the significant breakthroughs that have been made in medical and 
pharmaceutical sciences, a number of viral diseases (Acquired Immune Deficiency 
Syndrome), central nervous system disorders (Alzheimer‘s disease, Parkinson‘s 
disease and Huntington‘s disease), cancer and autoimmune disorders are still 
incurable (Hider, 1998).  There is therefore an unmet medical need for new drugs to 
treat these conditions.  Only the successful identification and development of novel, 
potent and efficacious compounds will solve this problem (Overbye and Barrett, 
2005). 
Proteins and peptides are increasingly recognised as potential leads for the 
development of new therapeutics for a variety of ailments (Tan et al., 2010).  Cyclic 
dipeptides (CDPs), a group of small bioactive peptides, are amongst the most 
common peptides found in nature.  Although some CDPs have been isolated from 
natural sources, the preparation of smaller peptides is often more practical by 
synthesis rather than extraction (Haywood, 2000). Even though CDPs have been 
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known for more than a century, only recently have they drawn attention due to the 
growing knowledge and understanding of the diversity and biological functions 
played by many of the cyclic dipeptides found in nature (Lucietto, 2004).  Their 
unusual heterocyclic system found in several natural products constitutes a rich 
source of biologically active compounds. The wide spectrum of their biological 
properties points to various therapeutic possibilities. These peptide-based agents 
have been shown to exhibit potential as antibiotics, muscle relaxants and anticancer 
compounds, as well as in the treatment of cardiovascular dysfunction (Milne et al., 
1998; Graz et al., 1999; Haywood, 2000). 
Unfortunately, their potential for development as therapeutics for clinical use is 
hindered by various obstacles to their successful delivery (Tan et al., 2010).  
Functional properties such as side chains, as well as terminal amino and carboxy 
groups can drastically limit the peptide‘s ability to permeate biological barriers and 
also restrict its access to the target site (Lambert et al., 2001).  For this reason, a 
carrier or delivery system for therapeutic proteins and peptides would be ideal. 
First designed in the 1960s, liposomes are spherical lipid bilayers ranging from 50 
nm to 1000 nm in diameter.  They are typically composed of phospholipids and 
cholesterol which self associate into bilayers to encapsulate an aqueous interior 
(Banerjee, 2001; Bawarski et al., 2008).  They serve as convenient delivery vehicles 
for biologically active compounds for the following reasons: They can be used to 
provide targeted (cellular or tissue) delivery of drugs; they help improve 
bioavailability of encapsulated drugs; they provide sustained release and can also be 
used to solubilise drugs for systemic use (Singh and Lillard, 2009); they contribute to 
increasing efficacy and minimizing toxicity of encapsulated compounds (Alipour et 
al., 2008).   
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1.2 Aims and objectives 
1.2.1 Aim 
 
There is a therefore an urgent need for new drug entities and novel approaches to 
drug formulation and drug delivery to combat bacteria, as the fight against multi-drug 
resistant (MDR) pathogens continues.  Towards this end, this study, which was 
designed to assess the antibacterial activity of cyclo(Tyr-Pro) aimed to optimize a 
liposomal formulation of cyclo(Tyr-Pro) using statistical methods and to test its 
antibacterial activity against various Gram-positive and Gram-negative bacteria. 
 
1.2.2 Objectives 
 
In order to achieve the aim several objectives were defined, and they were as 
follows: 
 Develop analytical methods to quantify liposomal cyclo(Tyr-Pro) formulations 
 Use response surface methodology (RSM) in conjunction with Central 
Composite Design (CCD) to establish the functional relationship between the 
factors (cholesterol and phospholipid content) and response (percent 
encapsulation and bacterial inhibition) of liposome encapsulated cyclo(Tyr-
Pro) 
 Find the level of each independent variable that would give a liposomal  
formulation that would yield an optimum response for each of the bacteria, 
namely the Gram-positive Staphylococcus aureus and Bacillus cereus and the 
Gram-negative Escherichia coli and Pseudomonas aeruginosa  
 
 Determine the MIC of the respective formulations against the bacteria. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Introduction 
 
All living beings are prey to infection, humans, being no exception, are at risk of 
contracting any number of diseases caused by viruses, bacteria, protozoa, fungi or 
helminths (Rang et al., 2007).  The development of antimicrobial drugs is one of the 
most significant therapeutic advances in the history of medicine, both in the control 
or cure of severe infections, and in the prevention and treatment of infectious 
complications of other therapeutic modalities such as cancer and surgery (Katzung, 
2007; Rang et al., 2007).  A noteworthy feature of antimicrobials is their selectivity for 
targets that are unique to microorganisms or targets that are much more important in 
microorganisms than in humans (Katzung, 2007), and they are illustrated in Figure 1 
(Walsh, 2003). 
Penicillins, cephalosporins, vancomycin and other β-lactams (carbapenems and 
monobactams) act by interfering with synthesis of the bacterial cell wall, a structure 
absent in host cells (Katzung, 2007; Rang et al., 2007).  Aminoglycosides and 
tetracyclines exert their chemotherapeutic effects on the 30S subunit of the bacterial 
ribosome, inhibiting protein synthesis at a translational level (Katzung, 2007; Rang et 
al., 2007).  Chloramphenicol, erythromycin and clindamycin also block bacterial 
protein synthesis at the translational level by interfering with the function of the 50S 
subunit of the bacterial ribosome (Katzung, 2007).  Rifampicin selectively inhibits 
bacterial DNA-dependant RNA polymerase, without affecting this enzyme in the host 
cell.   
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Figure 1: Metabolic pathways in the bacterial cell that are proposed to be targets for antibiotic action 
(Walsh, 2003) 
 
Sulphonamides contain a sulphanilamide moiety, a structural analogue of para-
aminobenzoic acid (PABA), an important enzyme in the synthesis of folate.  
Sulphonamides inhibit bacterial synthesis of folic acid by competing with PABA for 
transport into the bacterial cell thereby preventing the enzymatic incorporation of 
PABA into a precursor of folic acid (Rang et al., 2007).  Quinolones impair bacterial 
DNA synthesis by inhibiting DNA gyrase, the enzyme responsible for maintaining the 
helical structure of DNA (Katzung, 2007). Selected antibacterial agents, their modes 
of action and spectra of activity are summarized in Table 1. 
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Table 1: Summary of the mechanisms of action and spectrum of activity of selected antibiotic drugs 
(adapted from Katzung, 2007; Rang et al., 2007) 
Structure or process 
affected 
Drug Mode of action Spectrum of action 
Cell membrane Polymyxin Destroy cytoplasmic 
membrane of susceptible cells 
thereby interfering with the 
permeability of the 
membrane. 
Pseudomonas 
 Pyrazinamide Disrupts membrane transport Mycobacterium 
tuberculosis 
Cell wall Bacitracin Interferes with the movement 
of peptidoglycan precursors 
through the bacterial 
membrane to the cell wall  
Gram-positive 
bacteria 
 Beta-lactams Bind to and deactivate the 
enzyme that cross links the N-
acetyl muramic acid (NAM) 
subunits of peptidoglycan 
Gram-positive and 
some Gram-negative 
organisms 
 Cycloserine Analogue of alanine that 
interferes with the formation of 
alanine-alanine bridges 
between NAM subunits 
Some Gram-positive, 
mycobacteria 
 Ethambutol Prevents the formation of 
mycolic acid 
M. tuberculosis and 
M. leprae  
 Isoniazid Blocks the gene for an 
enzyme that forms mycolic 
acid 
M. tuberculosis and 
M. Leprae 
 Vancomycin Directly interferes with the 
formation of alanine-alanine 
bridges between NAM 
subunits 
Most Gram-positives, 
reserved for MRSA 
Protein synthesis Aminoglycosides Inhibit protein synthesis by 
irreversibly binding 30S 
subunit of prokaryotic 
ribosome resulting in 
mistranslation of mRNA by 
ribosome, production of 
aberrant proteins or 
premature release of 
ribosome from mRNA 
Gram-positive and 
Gram-negative 
bacteria 
 Chloramphenicol Prevents prokaryotic 
ribosomes from moving along 
mRNA by binding to their 50S 
subunit (inhibits peptidyl 
transfer reaction) 
Broad spectrum for 
both Gram-positive 
and Gram-negative 
bacteria 
 Lincosamines Binds to 50S subunit and 
prevents protein elongation 
Gram positive and 
Gram-negative  
bacteria 
 Macrolides Interfere with translation by 
binding to the 50S ribosomal 
subunit. 
Gram-positive and 
few Gram-negative 
bacteria 
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Table 1 continued.... 
Structure or process 
affected 
Drug Mode of action Spectrum of action 
 Tetracyclines Prevent  tRNA 
molecules which carry 
amino acids by binding 
to ribosomes at the 
30S docking site 
Gram-positive, Gram-
negative, mycoplasma 
Metabolism Dapsone Interferes with 
synthesis of folic acid 
M. tuberculosis, M. 
Leprae 
 Sulphonamides Analogues of PABA 
that that bind 
irreversibly to the 
enzyme that produces 
folic acid 
Gram-positive and 
Gram-negative, some 
fungi and protozoa 
 Trimethoprim Blocks second 
metabolic step in the 
formation of folic acid 
from PABA; synergistic 
with sulphonamides 
Gram-positive, Gram-
negative, some fungi 
and protozoa 
Nucleic acid 
synthesis 
Fluoroquinolones Inhibit DNA gyrase 
which is needed to 
correctly replicate DNA 
Gram-positive and 
Gram-negative 
 Nitroimidazoles Anaerobic conditions 
reduce the molecule 
which then damages 
DNA and prevents its 
correct replication 
Obligate anaerobic 
bacteria 
 Rifampin Binds to RNA 
polymerase preventing 
transcription of RNA 
Gram-positive and 
Gram-negative 
 
 
Overuse and inappropriate use of antibiotics has fuelled a major increase and 
prevalence of multi-drug resistant pathogens (Monroe and Polk, 2000; Katzung, 
2007).  Not long after the introduction of penicillin in the 1940s, resistance in some 
strains of Staphylococcus aureus developed.  Resistance to methicillin and, more 
recently, glycopeptides followed.  Following that, treatment of conditions commonly 
seen in the out-patient setting such as acute otitis media, acute cystits, conjunctivitis 
and acne became increasingly difficult (Monroe and Polk, 2000).   The evolution of 
multi-drug resistant bacteria no longer poses a concern in the hospital setting only; it 
is now being observed in the community as well (Zhang et al., 2008).  While over the 
past 20 to 30 years drug-resistant staphylococci and enterococci have posed a major 
concern to care-givers in hospitals, other Gram-positive organisms, namely, 
pneumococci have raised concerns in the community.  Today, this bacterium is 
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multi-resistant not only to penicillins, but to other beta-lactams, macrolides, 
sulphonamides, tetracyclines, and more recently, fluoroquinolones (Klugman et al., 
2004; Levy, 2005).  When introduced in the 1980s, fluoroquinolones, particularly 
ciprofloxacin, were regarded as the ‗new penicillins‘.  This is because they were safe, 
bactericidal and showed a broad spectrum of activity against bacteria.  Over the last 
10 years, the appearance of high-level fluoroquinolone resistance in Staphylococcus 
aureus, Pseudomonas aeruginosa, Escherichia coli and other clinically significant 
pathogens was observed (Levy, 2005).  Certain strains of Enterococcus faecium, 
Mycobacterium tuberculosis, Klebsiella pneumoniae and Acinetobacter baumanni 
are examples of such clinical isolates (Levy, 2005; Fischbach and Walsh, 2009).  
Over the past 20 years, clinicians and other healthcare professionals have faced 
hospital acquired methicillin-resistant Staphylococcus aureus (MRSA) which has 
resulted in many fatalities and is resistant to many other antibiotics.  Vancomycin has 
been the therapeutic answer to MRSA, but that is no longer so, as vancomycin 
resistance has emerged clinically (Levy, 2005).    
 
Subsequent to the wave of broad-spectrum antibiotics in the 1980s and 1990s, 
pharmaceutical companies focused on the development of narrow-spectrum 
antibiotics with Gram-positive activity. This has cast a shadow on the treatment of 
infections caused by Gram-negative organisms (Theuretzbacher, 2009).  Hospital-
acquired outbreaks of vancomycin-resistant enterococci and multi-drug resistant 
Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumani and Klebsiella 
pneumoniae infections are increasingly reported worldwide (Nordmann et al., 2007; 
Fischbach and Walsh, 2009).  Although less prevalent than MRSA, these organisms 
are resistant to some, or all of the current antibiotic classes used to treat Gram-
negative bacteria: the beta-lactam antibiotics, quinolones, aminoglycosides, 
tetracyclines and polymyxins (Falagas et al., 2005). A feature of Gram-negative 
bacteria which complicates the hope of finding antibiotics with Gram-negative activity 
is their outer membrane which restricts the entry of some antibiotics and the efflux 
pump which pumps out much of the remainder (Fischbach and Walsh, 2009).   Table 
2 lists some of the bacteria that are becoming problematic in the hospital and 
community settings. 
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Table 2: Recently emerging resistance problems (Levy, 2005) 
Hospital  Community 
Vancomycin-resistant, methicillin-
resistant Staphylococcus aureus (VRSA, 
MRSA)  
Community-associated methicillin-
resistant Staphylococcus aureus (CA-
MRSA) 
Carbapenem and extended spectrum β-
lactam-resistant enteric organisms 
(Escherichia coli, Klebsiella 
pneumoniae, Pseudomonas aeruginosa) 
Fluoroquinolone-resistant Neisseria 
gonorrhoeae 
Multi-drug resistant Acinetobacter 
baumannii  
Fluoroquinolone-resistant  Escherichia 
coli 
Fluoroquinolone-resistant  Escherichia 
coli 
 
 
A factor that worsens this situation is the fact that resistance, once acquired is not 
easily lost, instead the resistance genes form part of the organism‘s genetic code 
(Levy, 2005).  The problem of antibiotic resistance is complex and involves 
interaction of multiple factors relating to the particular organism, the drug being used 
as well as the environment (Monroe and Polk, 2000).  
   
2.2 Bacterial resistance to antibiotics  
 
Almost as soon as antibacterial drugs were discovered, bacteria responded by 
manifesting various forms of resistance.  In fact, Alexander Fleming the discoverer of 
penicillin, commented in the New York Times in 1945 that ―the microbes are 
educated to resist penicillin and a host of penicillin-fast organisms is bred out which 
can be passed to other individuals and from them to others until they reach someone 
who gets a septicaemia or pneumonia that penicillin cannot save‖ (Wright, 2005).     
 
Bacterial resistance can be classified into two broad types: Intrinsic and acquired.   
Intrinsic or innate resistance is a result of inherent characteristics of the bacterium.  It 
arises from the biology of the organism (e.g. barrier provided by outer membrane of 
Gram-negative bacteria) (Wright, 2005).  Acquired resistance happens when 
populations of bacteria that were initially susceptible to a certain antibacterial agent 
become resistant to that agent (Wright, 2005; Tenover, 2006).   Acquired resistance 
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is often caused by mutations in chromosomal genes, or by acquisition of mobile 
genetic elements, such as plasmids or transposons, which carry the antibiotic 
resistance genes (Wright, 2005; Rang et al., 2007).  
 
There are four major mechanisms of antibiotic drug resistance, which are due to 
chromosomal mutations, and they are illustrated in Figure 2. 
 
 
 
Figure 2: Four major mechanisms involved in bacterial resistance to antibacterial agents (Hawkey, 
1998) 
 
 The acquisition of an efflux pump which pumps the drug out of the bacterial 
cell before it reaches the target site, thereby preventing the drug from exerting 
the desired effect.   
 The organism synthesizes enzymes that selectively destroy the activity of the 
antibacterial agent 
 Bacteria acquire genes that enable them to cause mutations in key binding 
elements and this limits access of antibacterial agents to the intracellular 
target site (Wright 2005; Tenover, 2006). 
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 Reduced permeability of the outer membrane (especially in Gram-negative 
bacteria) (Hawkey, 1998) 
 
Susceptible bacteria acquire new genetic material from resistant bacteria through 
conjugation, transformation and transduction (Tenover, 2006).  During conjugation, 
there is a transfer of genetic material between bacteria.  Transduction involves the 
transference of genetic material from one bacterium to another via bacterial viruses 
and transformation happens when bacteria acquire and incorporate DNA segments 
from other bacteria that have released their DNA complement into the environment 
after lysis (Tenover, 2006; Rang et al., 2007).   
 
Apart from the introduction of carbapenems in 1985, many of the antibiotics in 
current use were discovered over 40 years ago.  Structural and chemical changes to 
these compounds continue to provide antibiotics that provide adequate therapy for 
bacterial infections.  Synthetic tailoring is a process of structural modification where 
the parent structure of a compound is left intact to preserve activity, while structural 
changes in the attached functional groups result in improvement of biological activity 
(Fischbach and Walsh, 2009).  Figure 3 illustrates synthetic tailoring of some of the 
well-known antibiotics.  Synthetic tailoring is done when bacteria become resistant to 
the existing compound e.g. second and third generation cephalosporins, cefaclor 
and ceftazidime, are more resistant to beta-lactamases than first generation 
cephalosporins, and can even penetrate the outer membrane of Gram-negative 
bacteria better than the first generation agents.  Emergence of beta-lactamases that 
breakdown third generation compounds prompted the development of cefepime, a 
fourth generation compound (Fischbach and Walsh, 2009).  
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Figure 3: Synthetic tailoring used to create successive generations of antibiotic classes (Fischbach 
and Walsh, 2009) 
 
However, further modifications are becoming significantly challenging.  The 
emergence of MDR pathogens as well as poor tissue distribution of otherwise 
effective antibiotics at the receptor site have led to treatment failures (Zhang et al., 
2008).    
 
2.3 Next generation antimicrobials: Peptide antibiotics 
 
Investigations into the development of new antibacterial agents to counteract 
resistance have intensified in recent years.  The search for compounds with 
antibacterial activity has led to the study of naturally occurring antimicrobial peptides 
as a foundation on which to target microorganism death by mechanisms that do not 
aid in the development of resistant strains (McInnes et al., 2000).  Examples of 
naturally occurring antimicrobial peptides include gramicidin S and bacitracin.  Both 
these compounds showed activity against most Gram-positive bacteria, anaerobic 
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cocci, neisseria, tetanus bacilli and diphtheria species.  Polymyxin B is a peptide that 
has activity against Gram-negative organisms (Katzung, 2007).   Cycloserine is a 
relatively small molecule consisting of a single cyclised D-amino acid.  Its 
mechanism of action involves interference of cell wall synthesis (Silver, 2006).  
Daptomycin is a peptide that has activity against Gram-positive organisms.  Its 
mechanism of action involves disruption of bacterial membrane potential as well as 
inhibition of lipoteichoic acid synthesis (Monaghan and Barrett, 2006).   Difimicin, 
friulimicin and mannopeptimycin are discussed in more detail below. 
 
2.3.1 Difimicin 
 
Difimicin is a member of a family of actinomycete-produced 18-membered 
macrocycles.  Compounds in this family differ in variations in the macrolide ring and 
in the nature and position of the acyl residue bound to the sugars, with an isopropyl 
ester being the major component at position 4 (Donadio et al., 2010), as illustrated in 
Figure 4. 
 
 
Figure 4: Structures of difimycin and friulimicin (Donadio et al., 2010) 
 
Difimicin inhibits transcription by binding preferably to the beta and sigma subunits of 
haloenzymes (Donadio et al., 2010).  Optimer Pharmaceuticals is developing 
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difimicin for the treatment of Clostridium difficile infections (CDI), the most common 
cause of health-care related infectious diarrhoea in developing countries (McDonald 
et al., 2005).  This compound also has activity against aerobic and facultative Gram-
positive bacilli, Bacteriodes sp and other Gram-negative anaerobes (Ackermann et 
al., 2004; Finegold et al., 2004).  In a phase III study, oral administration of this 
compound led to low (< 50 ng/ml) plasma and high stool concentrations (Louie et al., 
2009). 
 
2.3.2 Friulimicin 
 
Structurally, this compound belongs to the amphomycin family of cyclic lipopeptides 
(Figure 4) (Vértesy et al., 2000).  Recent studies have shown that friulimicin 
interrupts the cell wall precursor cycle through formation of a Ca2+-dependent 
complex with the bactoprenol phosphate carrier, C55-P, thus almost completely 
inhibiting lipid I formation. Since C55-P is involved in teichoic acid and capsule 
formation, this compound may inhibit many pathways that are crucial for the 
functioning of a Gram-positive cell envelope (Schneider et al., 2009; Donadio et al., 
2010).  Friulimicin has shown potent activity against many Gram-positive organisms, 
including strains that are resistant to traditional antibacterial agents (Schneider et al., 
2009).  In 2007, MerLion Pharmaceuticals announced the commencement of phase I 
clinical trials of a parenteral friulimicin formulation, but there have been no 
subsequent progress reports (Donadio et al., 2010).  
 
2.3.3 Mannopeptimycin  
 
This compound was first isolated in the 1950s from Streptomyces hygroscopicus (He 
et al., 2002), and is illustrated in Figure 5 below.  Mannopeptimycin inhibits the 
transglycosylation step of bacterial cell wall synthesis by binding to, and 
sequestering lipid II.  It has shown good in vitro activity against Gram-positive 
bacteria, including MRSA, VRE, and penicillin resistant Streptococcus pneumoniae 
(Singh et al., 2003).    
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Figure 5: Structure of mannopeptimycin (Donadio et al., 2010) 
 
Over the last two decades, the flow of new antibacterial drugs into the market has 
slowed, leaving a gap between the diagnosis of resistant pathogens and effective 
therapeutic options (Theuretzbacher, 2009).  In the past thirty years, the only truly 
novel agents that have been launched are linezolid (Pharmacia and Pfizer) and 
daptomycin (Cubist).  Concommitant with the development of these novel agents has 
been a decrease in the number of analogues generated of the classical antibiotics, 
predominantly beta-lactam antibiotics, tetracyclines, macrolides and quinolones 
(Overbye and Barrett, 2005).   The decline in antibacterial drug discovery, coupled 
with the increasing risk as a result of infections caused by drug-resistant bacteria 
pose a threat to health professionals (Theuretzbacher, 2009).   
 
Successful drug development entails a number of steps, one of which is ensuring 
interaction of the drug candidate with the target receptor, and attaining satisfactory 
intracellular delivery for drug candidates with receptors located inside the cell (Pujals 
and Giralt, 2008).  Proteins and peptides are increasingly recognised as potential 
leads for the development of therapeutics for a wide range of diseases (Tan et al., 
2010).  
 
More than 50 % of our 30 000 genes encode proteins, many of which have been 
shown to be valuable candidates for protein and peptide drug development.  The 
Pharmaceutical Research and Manufacturers of America‘s (PhRMA) report on 
―Biotechnology medicines in development‖ listed 633 new drug candidates relating to 
more than 100 diseases including cancer, infectious diseases, autoimmune 
diseases, HIV/AIDS and related conditions.  Among these, 66 were derivatives of 
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proteins or peptides (Tan et al., 2009).  As pharmaceutical development is moving 
toward rational drug design, where therapies are engineered to interfere with or 
block disease mechanism, peptides are gaining more and more importance as 
versatile intermediates and active materials (Bernagen, 1995). The importance of 
peptides as central modulators of many biological functions has become increasingly 
evident and this has lent them the potential to be among the major candidates in the 
search for new drugs (Haywood, 2000). They are already being used therapeutically 
in areas such as neurology, endocrinology and haematology.  Table 3 shows the 
major peptides and proteins currently used as drugs.  Most of these agents are 
prepared by recombinant technology and are used to supplement the action of 
endogenous mediators (Rang et al., 2007).     
Table 3: Peptide agents as drugs (Rang et al., 2007) 
Drug Use Route of administration 
Peptides 
Oxytocin 
Calcitonin 
Insulin 
Somatostatin 
Growth hormone 
Cyclosporin 
 
Induction of labour 
Paget‘s Disease of bone 
Diabetes 
Acromegaly 
Dwarfism 
Immunosuppression 
 
Injection 
Intranasal, injection 
Injection 
Intranasal, injection. 
Injection 
Oral 
Proteins  
Streptokinase 
Inteferons 
Erythropoietin 
Clotting factors 
Antibodies, vaccines 
 
Thromboembolism 
Tumor chemotherapy 
Anemia 
Clotting disorders 
Infectious diseases 
 
Injection 
Injection 
Injection 
Injection 
Injection, oral. 
 
 
With the advance of modern synthetic chemistry, more drugs of peptide origin are 
being used clinically (Frokjaer and Hovgaard, 2000).   
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2.4 Peptides and amino acids 
 
Peptides are compounds made up of amino acids which are connected by amide 
functions (Lucietto, 2004).  Peptide mediators typically consist of a linear chain of 
about 5 – 40 amino acids.   Amino acids are simple organic compounds and make 
up the building blocks of all protein and peptide molecules.  They are a special kind 
of carboxylic acid containing a basic amine (-NH2) group and an acidic carboxy (-
COOH) group (Campbell and Farrell, 2003).  Individual amino acids can be 
connected by the formation of covalent bonds between them.  Water is eliminated 
during the process and a bond is formed between the α-carboxy group of one amino 
acid and the α-amino group of the next one, as illustrated in Figure 6.  A bond 
formed in this way is called a dipeptide bond (Campbell, 1995).  
 
 
Figure 6: Formation of a dipeptide bond between amino acids (Bio Info Library Bank, 2009) 
 
Proteins of all species, from bacteria to humans, are made up from the same set of 
20 standard amino acids, which are the most commonly found of the approximately 
80 amino acids known to date (Wade, 1995).   All but one are α-amino acids with a 
primary –NH2 group and a –COOH attached to a central carbon atom, the α-carbon 
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(Cα).  Also attached to the Cα atom are a hydrogen atom and a side chain ‗R‘ group.  
The one exception to this general rule is proline, which has a secondary amino group 
and is therefore really known as an α-imino acid (Lehninger et al., 1993).  The 
general structure of an amino acid is depicted in Figure 7. 
 
 
Figure 7: General structure of an α-amino acid with the amino group on the left and carboxy group on 
the right (Protocol Supplements, 2009). 
 
The twenty naturally occurring amino acids are illustrated in Figure 8 and are 
grouped according to the chemical similarity of the R-group as follows: non-polar, 
aliphatic, polar uncharged, aromatic positively charged and negatively charged 
(Lehninger et al., 1993). 
The value of amino acids as biological building blocks can be ascribed to their ability 
to form peptide bonds with one another (McMurry, 2000).  Apart from the metabolic 
roles they play, amino acids are also key precursors to many hormones and 
neurotransmitters (Campbell and Farrell, 2003).    
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Non-polar aliphatic R-groups 
      
Alanine Glycine Proline Valine Leucine Isoleucine 
Polar, uncharged R-groups 
      
Serine Cysteine Threonine Methionine Asparagine Glutamine 
Aromatic R-groups 
   
Phenylalanine Tryptophan Tyrosine 
Positively charged R-groups 
   
Histidine Arginine Lysine 
Negatively charged R-groups 
  
Aspartic acid Glutamic acid 
Figure 8: The twenty standard amino acids of proteins (Lehninger et al., 1993) 
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The broad spectrum of mediator functions of peptides affords them numerous 
opportunities for therapeutic use.  They are used by many tissues for cell-to-cell 
communication and play key roles in both autonomic and central nervous system 
function.  Peptides constitute a class of organic molecules that control, catalyse and 
modulate many biological processes.  They play an important role as hormones, 
neurotransmitters and neuromodulators (Rang et al., 2007).  The importance of 
peptides in rational drug design can be attributed to the following:  the metabolism 
and pharmacokinetics can be easily determined, except for glycine, amino acids 
contain multiple chiral carbons which can function to increase receptor specificity, 
thereby minimising drug toxicity and lastly, the synthesis of small peptides is 
relatively simple and economical (Vogler et al., 2002).   
A difficult element in the development of peptide-based pharmaceuticals, which 
affects both their therapeutic potential and clinical application, is dealing with their 
physical and chemical instability (Tan et al., 2009).  This is because the linear form 
of the peptide is often less stable in vivo, in acidic media, and if absorbed, is broken 
down very rapidly (Mizuma et al., 1998; Lambert et al., 2001).  Functional properties 
such as side chains and terminal amino and carboxy groups can drastically limit the 
peptide‘s ability to permeate biological barriers and also restrict its access to the 
target site (Lambert et al., 2001).  This matter of reduced receptor specificity leading 
to poor receptor interaction is countered by the introduction of structural rigidity 
through peptide cyclization, which enhances the activity of linear peptides (Grant, 
2002).  Because of structural similarity of cyclic dipeptides (CDPs) to linear peptides, 
their appearance in biological compounds has encouraged researchers to use them 
to evade the limitations of linear peptides (Dinsmore and Beshore, 2002).  By virtue 
of their unique structures, CDPs offer innovative solutions to the challenges 
surrounding drug design (Grant, 2002).  To appreciate the impact that these simple 
compounds have made in this field, the limitations of linear peptides as drug 
candidates are addressed by their cyclic counterparts. 
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2.5 Cyclic dipeptides 
2.5.1 What are cyclic dipeptides? 
 
Cyclic dipeptides (CDPs) or 2,5-diketopiperzines (DKPs) are heterocyclic 
compounds consisting of two amino acid residues linked to a central 
diketopiperazine structure (Kilian, 2002).  This is illustrated in Figure 9 where R1 and 
R2 can be substituted with different amino acid side-chain residues, resulting in a 
number of chemical structures with varying chemical and biological properties.  
 
O
NH
O
NH
R1
R2
 
Figure 9: General structure of 2,5-diketopiperazines (Kilian, 2002) 
 
CDPs are synthesized from linear peptides by either ‗backbone to backbone‘ 
cyclization resulting in the formation of an amide bond between the N-terminal and 
the C-terminal of the amino acid residues, or by cyclizations involving the side chains 
of individual amino acids (Li and Roller, 2002).  CDPs have been known since the 
beginning of this century and are the simplest form of cyclic dipeptide known, with 
the simplest being cyclo(Gly-Gly) (Prasad, 1995).   
 
Before the 1970s, little attention was given to CDPs, largely because of the 
seemingly inert nature of the simpler members of this group of peptides (Sammes, 
1975).  Recently, there has been a growing awareness of the biological roles played 
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by some DKPs found in nature (Prasad, 1995), as well as a growing recognition of 
the diversity of structural types within this group of natural products (Sammes, 1975). 
Being relatively simple compounds, they are amongst the most ubiquitous peptide 
derivatives found in nature.  Simple DKPs have been shown not only to exist alone 
or as part of larger, more complex molecules, but also to be enzymatically 
synthesized in several members of the animal and plant kingdoms (Prasad, 1995; 
Martins and Carvalho, 2007).  Examples of these compounds are represented in 
Table 4.   
 
Table 4: Simple DKPs that occur naturally (adapted from Sammes, 1975; Prasad, 1995) 
DKP Species Common name 
Cyclo(Pro-Leu) Rosellinia necatrix 
Aspergillus fumigatus 
Fungus 
Fungus 
Cyclo(Pro-Val) Rosellini necatrix 
Aspergillus ochraceus 
Metarhizium anisopliae 
Fungus 
Fungus 
Fungus 
Cyclo(Pro-Phe) Rosellini necatrix Fungus 
Cyclo(Phe-Phe) Penicillum nigricans 
Streptomyces noursei 
Fungus (Mould) 
Cyclo(Ala-Leu) Aspergillus niger Fungus (Black mould) 
Cyclo(Pro-Trp) Penicillum brevicompactum Fungus 
 
 
2.5.2 Why cyclic dipeptides?  
 
Although the existence of CDPs has been known since the beginning of the century, 
they have only recently drawn a considerable amount of interest (Graz et al., 1999).  
This is possibly because a large number of naturally occurring CDPs have more 
recently been shown to possess powerful and useful biological effects.  This can be 
attributed to their high affinity to bind to certain receptors in prokaryotes and 
eukaryotes (Milne et al., 1998; Lambert et al., 2001).  Due to their chiral, rigid and 
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functional structure, they can interact with a number of different receptors with high 
affinity, giving them a wide range of biological functions, and are thus considered 
ideal for the rational design of new therapeutic agents (Martins and Carvalho, 2007).       
A large number of drugs today are made up of peptides in some form.  Cyclo(His-
Pro) is found throughout the CNS and GIT (Miyashita et al., 1993).  This compound 
has been found to inhibit the release of prolactin from the pituitary (Jikihara et al., 
1993), it has also been found to play an important role in the perception of pain 
induced by physical, mechanical, thermal and chemical stimuli (Prasad, 1995).  
Although the mechanism of action of cyclo(His-Pro) is unknown, it is assumed that 
more than one mechanism is responsible for its biological action (Prasad, 1995).    
The CDP cyclo(Leu-Gly) is structurally related to oxytocin (Cys-Tyr-Ile-Glu-Asn-Cys-
Pro-Leu-Gly-NH2) and to the melanocyte-stimulating hormone release enzyme 
inhibiting factor (Pro-Leu-Gly-NH2) (Prasad, 1995).  It has been shown that 
cyclo(Asp-Pro) and cyclo(His-Pro) possess anorexogenic properties, in contrast to 
their linear analogues, which have no effect on food intake in rats (Lin et al., 1994).  
The effects of cyclic dipeptides on certain biological systems are depicted in Table 5 
below. 
Table 5: Examples of biological activity exhibited by cyclic dipeptides (Brauns, 2004) 
Activity Cyclic dipeptide 
Immunomodulation Cyclo(Arg-Lys), cyclo(Asp-Lys) 
Modulation of glucose metabolism 
Hormonal regulation 
Cyclo(His-Pro) 
Anticonvulsant Cyclo(Gly-Phe), cyclo(Ala-Phe) 
Antibacterial Cyclo(Trp-Trp), cyclo(Trp-Pro), cyclo(Phe-
Pro), cyclo(Tyr-Pro) 
Inhibition of cell division Dehydro derivatives of cyclo(Phe-Phe) 
Inhibition of dietary intake Cyclo(Asp-Pro) 
Induction of differentiation in cancer cell lines Cyclo(Phe-Pro), cyclo(Tyr-Pro), cyclo(Pro-
Pro), cyclo(Trp-Trp) 
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Numerous reports have identified cyclic dipeptides as having potential as antibiotics, 
toxins, hormones and ion transport regulators (Lin et al., 1994; Prasad et al., 1997).  
Some have even been shown to possess antiviral and antitumor activity (Kopple, 
1972).  Milne and others (1998) showed that CDPs exhibit cardiac activity.  
Additionally, this study showed that cyclic dipeptides have potential as muscle 
relaxants, antitumor compounds and antimicrobial agents.   
Cyclic dipeptides have been synthesized, and studied, both structurally and 
functionally in the Cyclic Peptide Research Unit at the Nelson Mandela Metropolitan 
University since 1998 (Milne et al., 1998; Graz, 2002).  Selected CDPs previously 
tested showed marked antibacterial activity (Milne et al., 1998; Graz, 2002). A study 
conducted by Graz (2002) investigated the antimicrobial effects of 24 CDPs.  The 
antibacterial and antifungal activity of these compounds was measured against the 
Gram-negative bacteria Escherichia coli, Pseudomonas aeruginosa, Klebsiella 
pneumoniae; the Gram-positive Staphylococcus aureus, Bacillus subtilis and 
Streptococcus pneumoniae and the fungi Candida albicans, Aspergillus niger and 
Penicillium notatum, by means of the Kirby-Bauer Assay.  The results indicated that 
proline-containing CDPs were the most effective in terms of antibacterial activity.  
Since then, the antimicrobial potential of numerous other cyclic dipeptides has been 
investigated, with some showing promising potential (Grant, 2002; Cunningham, 
2006; Janse van Rensburg, 2006).  The antimicrobial properties of cyclo(Phe-Cys) 
and cyclo(Tyr-Cys) determined by van der Merwe (2005) showed that these 
compounds did possess significant antibacterial activity.  Cyclo(Tyr-Cys) showed no 
activity against S. aureus, E. coli, P. aeruginosa and S. choleraestius  at a 
concentration of 500 µM and only a slight inhibition of S. pyogenes and B. subtilis; 
whilst cyclo(Phe-Cys) only inhibited E. coli and B. subtilis.  The antimicrobial activity 
of the isoleucine-containing CDP cyclo(Gly-Ile) also failed to significantly inhibit 
growth in Gram-positive bacteria but did cause inhibition of Gram-negative bacteria 
and C. albicans (Huang, 2006). 
 
The compound under investigation in this current study was cyclo(Tyr-Pro), 
illustrated in Figure 10 and consists of two amino acids, namely tyrosine and proline.   
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Figure 10: Structure of cyclo(Tyr-Pro) 
 
A large number of proline-based CDPs occur naturally in the plant and protist 
kingdoms (see Table 4).  In addition to their widespread occurrence, a number of 
proline-based CDPs have the ability to affect important biological processes (See 
Table 5).   Tyrosine-based CDPs have also been shown to possess antibacterial 
activity.   As part of a program investigating CDPs with an internal aromatic 
hydrophobic scaffold as potential novel antibacterial agents, Boyle and others (2008) 
explored the synthesis of tyrosine-based systems.  The result was a modest 
antibacterial activity against Staphylococcus aureus.  The most active compound 
tested was a dityrosine peptide with an MIC of 15.6 µg/ml (Boyle et al., 2008).  Both 
tyrosine and proline-based cyclic peptides have thus been found to possess some 
degree of antibacterial activity (Graz, 2002; Boyle et al., 2008).  Furthermore, Graz 
(2002) reported that Gram-positive organisms as a group were mainly inhibited by 
proline-containing and aromatic amino acid-containing CDPs, whilst Gram-negative 
organisms were inhibited by CDPs containing any amino acid, but cysteine.  
Microbial resistance to antimicrobial agents is on the rise, there is therefore an 
urgent need for new compounds.  Hancock and Lehrer (1998) stated the following, 
―antimicrobial peptides have a great potential to be the next breakthrough class of 
antimicrobials and the first truly novel class of antibiotics in thirty years.‖ 
The application of cyclic dipeptides as therapeutic drugs is also impeded by a 
number of disadvantages.  Permeation through biological membranes is hindered by 
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the presence of charged functional groups attached to the amino acid groups, which 
also affect the solubility of these compounds and ultimately their biological activity 
(Haywood, 2000; Jamie, 2002; Singh and Lillard, 2009).  Furthermore, many of these 
agents show more specificity at a molecular rather than cellular level.  Due to 
passive diffusion of drugs in the body, a small portion gets to the target site while the 
majority causes toxicity in other organs.  This requires administration of higher drug 
doses to obtain therapeutic effects, with resultant toxicity (Zelphati and Szoka, 1996).  
Thus, in order to optimize their biological activity, the use of specialized drug delivery 
systems is justified.  Liposomes provide one such example.  The encapsulation of 
peptides into liposomes is useful for the following reasons: 
 Protection of the peptides from enzymatic degradation 
 Improvement of cellular uptake into several cell types 
 Modification of intracellular peptide distribution (Zelphati and Szoka, 1996). 
The function of nanoparticles in targeted drug delivery was reviewed over two 
decades ago (Douglas et al., 1987).  Since then, considerable advancement has 
been made in the development of nanoparticulate drug carrier systems, prepared 
from a wide variety of raw materials.  Notwithstanding rigorous research on a variety 
of nanoparticulate systems, liposomes are still the most common colloidal drug 
delivery system in terms of marketed pharmaceuticals (Van Winden et al., 1997).    
 
2.6 Liposomes 
 
2.6.1 What are liposomes? 
In the early 1960s, researchers at Cambridge University observed how 
phospholipids formed multi-layered vesicles when dispersed in water.  It was 
demonstrated that each layer was a bimolecular lipid membrane and that the layers 
encircled an internal aqueous compartment (Bangham and Horne, 1964).  
Liposomes are thus colloidal drug carriers dispersed in water or aqueous surfactants 
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and are generally made up of an aqueous core having a phospholipid surface 
(Samad et al., 2007), as seen in Figure 11.  
 
 
Figure 11: Structure of a liposome (Avanti Lipids, 2009) 
 
Even though the lipid constituent of liposome formulations can vary, the natural 
phospholipid, phosphatidylcholine (PC), or synthetic derivatives thereof, listed in 
Table 6, is still the most commonly used lipid in the manufacture of pharmaceutical 
liposomes (Storm and Crommelin, 1998).   
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Table 6: Phospholipids and cholesterol used for the preparation of liposomes (Samad et al., 2007) 
Phospholipids Abbreviation Charge Tc (0c)a Mol. Wt.b 
Cholesterol CH 0 -- 387 
Dimyristoyl phosphatidylcholine DMPC 0 23 678 
Dipalmitoyl phosphatidylcholine DPPC 0 41 734 
Distearoyl phosphatidylcholine DSPC 0 58 790 
Dioleyl phosphatidylcholine DOPC 0 -22 786 
Dilauryl phosphatidylglycerol DLPG -1 4 633 
Dimyristoyl phosphatidylglycerol DMPG -1 23 689 
Dipalmitoyl phosphatidylglycerol DPPG -1 41 745 
Distearoyl phosphatidylglycerol DSPG -1 55 796 
Phosphatidyl ethanolamine PE 0 48 720 
Dimyristoyl phosphatidyl 
ethanolamine 
DMPE 0 - 636 
Dipalmitoyl phosphatidyl 
ethanolamine 
DPPE 0 60 692 
Distearoyl phosphatidyl 
ethanolamine 
DSPE 0 - 784 
Dimyristoyl phosphatidic acid DMPA -2 51 618 
Dipalmitoyl phosphatidic acid DPPA -2 67 649 
Dioleoyl phosphatidic acid DOPA -2 - 701 
Dipalmitoyl phosphatidylserine DPPS - 48 758 
Dicetyl phosphate DCP -1 - 547 
a: Tc: Transition temperature (º C); b: Mol.wt - molecular weight (g/mol) 
 
Because of their biphasic nature, liposomes can act as carriers for both lipophilic and 
hydrophilic drugs.  Highly hydrophilic drugs are located exclusively in the aqueous 
compartment, whilst highly lipophilic drugs are entrapped almost completely within 
the lipid bilayer (Immordino et al., 2004).   
The reasons why liposomes drew an interest as a potential drug delivery system 
were based on expectations of good biocompatibility, low toxicity and a lack of 
immune responses (Sharma and Sharma, 1997).  These suppositions came about 
because liposomes are typically made up of lipids forming bilayers that bear a 
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structural similarity to cell membranes, but without all the proteins (Woodle and 
Storm, 1998).   Additionally, their internal aqueous phase surrounded by a lipid 
bilayer suggested they would be suitable for the administration of both hydrophobic 
and hydrophilic drugs.  However, early research was plagued with problems which 
included insufficient understanding of liposome disposition and clearance in vivo, 
lack of sufficient understanding of liposome-cell interactions or liposome targeting 
data, insufficient stability and circulation time of liposome-based drugs (Lian and Ho, 
2000; Rodney and Milo, 2003).  Later advances included a better knowledge of lipid 
polymorphisms, physiological mechanisms of in vivo liposome distribution and lipid-
drug and lipid-protein interactions.  These advances resulted in liposome designs 
with improved stability, biodistribution and prolonged persistence in the bloodstream 
giving them more time to reach target tissues (Woodle and Storm, 1998).    
 
2.6.2 Classification of liposomes 
 
Liposomes can be categorized on the basis of composition as well as their 
interaction characteristics.  They are synthesized from either natural or synthetic 
phospholipids, or both, and are classified as follows based on their mechanism of 
intracellular delivery:  liposomes with non-specific reactivity (conventional 
liposomes), inert liposomes (sterically stabilised or long-acting liposomes), liposomes 
with specific reactivity due to attached ligands (targeted liposomes) and reactive 
liposomes which change structure upon interaction (cationic liposomes) (Lasic, 1997; 
Sharma and Sharma, 1997).   
They are also classified according to size and number of layers according to the 
various ways in which they are prepared as follows: Multi lamellar vesicles (MLVs), 
large unilamellar vesicles (LUVs) and small unilamellar vesicles (SUVs). 
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2.6.2.1 Classification on the basis of composition and intracellular delivery 
 
Conventional liposomes (CL) can be described as liposomes that are typically made 
up of only phospholipids (neutral and /or negatively charged) and/or cholesterol.  
These types of liposomes are rapidly taken up by the phagocytic cells of the 
reticuloendothelial system (RES) and hence exhibit a short circulation half-life.  They 
localize mostly in the liver and spleen (Sharma and Sharma, 1997).  A rational 
translation of this RES-directed uptake is that CL would serve as excellent drug 
delivery vehicles when the RES is the therapeutic goal (Storm and Crommelin, 
1998).   Conventional liposomes have been used for targeting of immunosuppressive 
drugs to lymphatic tissues such as the spleen.  In a pre-clinical model, an increase in 
immunosuppressive activity i.e. a delay in heart transplant rejection was seen with 
CL-encapsulated methylprednisolone (Binder et al., 1994). 
 
The development of long circulating liposomes (LCL) also known as sterically 
stabilized liposomes, represented a milestone in liposome research (Storm and 
Crommelin, 1998).  In spite of the benefit of CL in RES-directed treatment, their rapid 
clearance from circulation diminished their therapeutic application for diseases 
involving other tissues (Storm and Crommelin, 1998).  Most of the first studies 
involving sterically stabilized liposomes used either GM1 ganglioside or phosphatidy 
inositol (PI) as the stabilizing agent (Banerjee, 2001).  They are now commonly 
produced by covalently binding the hydrophilic polymer, polyethylene glycol (PEG) to 
the liposome bilayers.  These PEG groups are bulky and prevent interactions with 
molecular and cellular components in the biological environment (Crommelin et al., 
2003).  They demonstrate a longer circulation half-life when compared to CL 
because of the reduced recognition and reduced uptake by the RES (Kozlowska, 
2009). An important feature of LCL is their ability to leave the vascular system at 
body sites where the permeability of the vascular wall is increased (Lasic, 1998).  
This typically occurs at sites of infection, tumor growth or inflammation, where 
vascular permeability is compromised (Storm and Crommelin, 1998) and thus 
promotes their accumulation in these tissues. 
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The use of PEGylated liposomes to encapsulate oncologic agents has resulted in a 
modified biodistribution of the drug; their distribution away from the heart where 
significant toxic effects could be exerted, in addition to enhanced uptake by solid 
tumor tissue.  Doxil® is made up of PEGylated liposomes encapsulating the 
oncologic agent doxorubicin.  The prolonged circulation and small size of the 
vesicles enhance their accumulation in tumor tissue (Woodle and Storm, 1998; 
Crommelin et al., 2003). 
 
Immunoliposomes are LC or LCL with an antibody or recognition sequence attached 
(Crommelin et al., 2003).  These liposomes are designed to recognize and bind to 
specific cells in vivo and have specific fragments on their surface to enhance target 
site binding (Banerjee, 2001).   Immunoglobulins (Ig) of the IgG class and their 
fragments are the most commonly used targeting moieties.  Immunoliposomes are 
formed by covalent binding of these moieties to the liposome surface or their 
insertion into the liposome membrane (Torchilin, 2005).   
 
Cationic liposomes have a net positive charge and are also known as liposomal DNA 
delivery vectors (Banerjee, 2001).  They typically consist of DOPE and a lipophilic 
anionic component.    The positively charged lipid sections of the liposome interact 
with, and neutralize anionic DNA and thus promote condensation of the DNA into a 
more compact structure (Mahato et al., 1997; Crommelin et al., 2003).  Cationic 
liposome formulations exhibit high affinity for cell membranes and can be used to 
deliver exogenous material intracellularly (Banerjee, 2001).  At low pH, they fuse with 
the cell membrane and release their contents into the cytoplasm (Mahato et al., 
1997).  They are suitable for the intracellular delivery of weak bases and 
macromolecules (Sharma and Sharma, 1997). The different liposome types are 
illustrated in Figure 12 below. 
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Figure 12: Development of the liposome. A: Conventional liposomes with water-soluble drug in 
aqueous interior (a) and insoluble drug in membrane (b); B: Immunoliposome with covalently bonded 
antibody (c) and anchored in membrane (d); C: LCL with PEG (e) protecting liposome from 
opsonizing proteins (f); D: LCL immunoliposome, E: New age liposome which can be modified in 
many ways to act interact with various receptors or cellular components (Torchilin, 2005) 
 
2.6.2.2 Classification according to size and number of layers 
 
Liposome size can range from very small (0.025 μm) to large (2.5 μm) vesicles.  
Furthermore, they may have single or multiple bilayer membranes.   Liposome size 
is an important characteristic in determining the circulation half-life of liposomes and 
both the size and number of lamellae affect the degree of drug encapsulation 
(Sharma and Sharma, 1997).  Liposomes can be divided into one of these three 
categories:  Multi lamellar vesicles (MLVs), large unilamellar vesicles (LUVs) and 
small unilamellar vesicles (SUVs). 
MLVs – Their usual size is greater than 0.5 to 20 μm (Taylor and Morris, 1995; Storm 
and Crommelin, 1998).  They have more than one bilayer.  The standard preparation 
of MLVs is by gently dispersing phospholipids in aqueous media (Bangham and 
Horne, 1964).  The simplest and most widely used method for their preparation is the 
thin-film hydration method, in which a thin film of lipids is hydrated with a buffer at a 
temperature above the transition temperature of the lipids (Sharma and Sharma, 
1997; Lasch et al., 2003).  MLVs provide a greater encapsulation for lipophilic drugs 
and are mechanically stable on storage.  MLVs are rapidly cleared by the RES and 
are hence useful for targeting the cells of the RES (Banerjee, 2001). 
 
LUVs are typically sized from 100 nm to 1.0 μm, but unlike MLVs, contain only a 
single bilayer (Taylor and Morris, 1995).  They are prepared by detergent dialysis, 
ether injection, reverse-phase evaporation (REV) or active loading methods (Taylor 
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and Morris, 1995; Storm and Crommelin, 1998).  LUVs are 3 – 4 times more efficient 
at solute entrapment than MLVs, especially those prepared by REV, although they 
seem to share many physical properties (Juliano and Layton, 1980).  They are useful 
for hydrophobic drugs and provide a good entrapment of macromolecules.  LUVs are 
also rapidly cleared by the RES (Banerjee, 2001).   
 
SUVs – Sonication or extrusion of MLVs or LUVs results in SUVs.   They can also be 
prepared by active loading and solvent injection techniques.  They are generally 20 
nm to 100 nm in size and have a single bilayer (Taylor and Morris, 1995; Storm and 
Crommelin, 1998).   SUVs are thermodynamically unstable and are susceptible to 
aggregation and fusion at low or no charge. They provide limited entrapment of 
macromolecules and have a long circulation half-life (Sharma and Sharma, 1997; 
Banerjee, 2001). 
 
2.6.3 Medical applications of liposomes 
 
Liposomes have been widely considered as potential drug delivery systems ever 
since the published observation by Bangham and Horne (1964).   They have been 
investigated extensively for over 20 years and the findings of most of these studies 
have shown their adaptability to accommodate a large variety of drugs for a wide 
range of therapies (Storm and Crommelin, 1998).  The aim of any drug delivery 
system is to modulate the pharmacokinetics and/or tissue distribution of the 
contained drug in a beneficial way (Storm and Crommelin, 1998; Singh and Lillard, 
2009). In the late 1960s and 70s it was apparent to a number of researchers that 
biological compounds such as drugs and enzymes could be entrapped within 
liposomes and that the entrapped material would be handled differently from 
unencapsulated substance by cells or tissues (Juliano and Layton, 1980).   
Liposomes have been used to incorporate a wide variety of proteins and peptides 
(e.g. insulin), liposome-based DNA vaccines, radioactive atoms for imaging and 
biodistribution studies (e.g. Gallium-67 and Carbon-11), oncologic agents (e.g. 
liposomal vincristine and doxorubicin) as well as antimicrobial agents (e.g. 
amphotericin B) (Woodle and Storm, 1998;  Torchilin et al., 2005).  
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Early work by a number of researchers established the possibility of using liposomes 
as vehicles for drugs and macromolecules capable of modifying the activities of cells 
in vitro and in vivo.  One of the key properties that make liposomes resourceful drug 
carriers is their ability to modify the pharmacokinetics of encapsulated drugs. The 
change in absorption and metabolism of liposome-encapsulated drugs is significant 
when compared to the same compound in aqueous solution, with improvement in 
both the efficacy and toxicity profile of the liposomal compound (Lian and Ho, 2001).  
To understand how liposomes can be used to improve the performance of the 
enclosed drug, it may be useful to consider the following basic reasons for using 
liposomes as a drug carrier: 
 
2.6.3.1 Intracellular drug delivery 
 
 Certain drugs with intracellular targets are required to cross the plasma membrane 
for biological activity.  Liposomes can interact with target cells in various ways and 
are therefore able to promote intracellular delivery of drugs that in their free form 
would be unable to enter the cell due to unfavourable physicochemical 
characteristics. A common feature of peptides, proteins, nucleic acids and certain 
anticancer drugs is their low cellular permeability as well as chemical and enzyme 
instability (Momekova et al., 2007).   Liposome encapsulation of these agents 
protects them from extracellular degradation and promotes their delivery to the 
desired site of action.  The inclusion of positively charged lipids in the liposome 
formulation encapsulating particularly nucleic acids and negatively charged proteins 
results in a strong association of the contents with the liposome.  Cationic lipids 
exhibit considerable fusogenic activity which serves to improve cytosolic delivery of 
encapsulated drugs (Felnerova, 2004; Obata et al., 2010). 
 
2.6.3.2 Sustained release drug delivery 
 
Liposomes can act as a reservoir from which the encapsulated compound is 
gradually released.  This is particularly important for drugs that have a rapid 
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metabolism but require plasma concentrations at therapeutic levels for prolonged 
periods for maximum pharmacological activity.  The net effect is a longer duration of 
action and a reduction in frequency of administration (Sharma and Sharma, 1997; 
Storm and Crommelin, 1998).  In animal studies, liposome-encapsulated tobramycin 
resulted in high and sustained drug levels, about sixteen hours, when compared to 
free tobramycin which was cleared within one to three hours from the lungs of 
infected rats (Omri and Ravaoarinoro, 1996).  Encapsulation of ciprofloxacin into 
liposomes in the study by Webb et al. (1998) significantly increased its longevity in 
the plasma when compared to its free counterpart after intraperitoneal administration 
in rats infected with Salmonella typhimurium.    Wang et al. (2009) demonstrated that 
the drug release of topotecan, an anticancer agent which had been reported to tend 
to leak rapidly from vesicles, formulated by freeze-drying double emulsions (FDE) 
could be successfully controlled by manipulating the physicochemical properties of 
the incorporated drug.    Methods commonly employed in the control of liposomal 
drug release include protonation, precipitation or transition metal complexation, with 
resultant half-lives of up to 36 hours (Abraham et al., 2004; Zhigaltsev et al., 2006; 
Wang et al., 2009).   
 
2.6.3.3 Site avoidance delivery 
 
Many agents used in the treatment of cancer usually have a narrow therapeutic 
index and can be highly toxic to normal tissues.  Liposomes are poorly taken up by 
tissues of some of the major organ systems e.g. the heart, kidney and the GIT which 
are the major sites for toxic side effects of a number of anticancer agents (Sharma 
and Sharma, 1997).  Liposome formulations thus favourably influence the 
pharmacokinetics of these agents by reducing their distribution to sensitive tissues 
thus reducing toxicity and improving distribution to target tissues, thereby improving 
their efficacy (Omri et al., 2002). 
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2.6.3.4 Site-specific delivery 
 
This concept, first introduced by Paul Elrich involves liposome-mediated delivery of 
the drug to the desired site of action through contact-facilitated drug delivery, thus 
enhancing therapeutic efficacy (Sharma and Sharma, 1997).  Site-specific or 
targeted delivery can be achieved by employing active or passive methods (Singh 
and Lillard, 2009).  
 
Passive targeting exploits the natural tendency of certain cells, e.g. Kupffer cells in 
the liver and circulating macrophages of the RES to engulf foreign bodies (Lian and 
Ho, 2001).  Liposomes are cleared rapidly from circulation via uptake by resident 
phagocytic cells of the RES.  This can be exploited advantageously in passively 
targeting liposomes to these areas for delivery of certain antineoplastic agents and 
diagnostic imaging agents (Sharma and Sharma, 1997; Barenholz, 2001; Torchilin, 
2005). 
 
For certain drug delivery applications, an active delivery system that can promote 
binding to a particular cell-type within a given tissue may be necessary (Banerjee, 
2001).  The majority of active liposome target delivery systems use chemically 
coupled ligands expressed on liposome membranes to interact with functional 
groups or receptors on target cells (Singh and Lillard, 2009).  A number of different 
ligands or receptors such as antibodies, growth factors, cytokines, hormones and 
toxins have been bound or expressed on liposome surfaces to ensure that drugs, 
proteins and nucleic acids can be administered to target cells (Banerjee, 2001). 
 
2.6.3.5 Formulation aid 
 
Hydrophobic drugs such as cyclosporin are usually formulated in surfactants and 
organic co-solvents for systemic administration which often results in toxicity at the 
doses necessary to deliver the drug.  Liposomes however comprise of lipids which 
are fairly non-toxic, non-immunogenic, biocompatible and biodegradable, and can 
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encapsulate a wide range of lipophilic drugs (Sharma et al., 1997; Samad et al., 
2007).   
  
The first therapeutic liposome products were formulations of the effective but 
insoluble antifungal agent amphotericin B.  The toxicity of the encapsulated 
amphotericin B was significantly reduced when compared to its free counterpart but 
the efficacy was equivalent (Woodle and Storm, 1998). Liposomes are appropriate 
vehicles for the delivery of antimicrobial agents as they usually provide a sustained 
release drug effect. Studies conducted by a number of other researchers have 
proven the therapeutic benefits of liposome encapsulated antimicrobial agents as 
opposed to their free counterparts in terms of pharmacokinetics and efficacy 
(Beaulac et al., 1996; Omri and Ravaoarinoro, 1996; McAllister et al., 1999; Omri et 
al., 2002).  
Novel drug delivery systems such as liposomes are developed in a time when the 
current formulation is not satisfactory and reformulation offers improved therapeutic 
advantage and safety over the old formulation.  
  
2.6.4 Mechanisms of intracellular liposomal distribution  
 
For drug delivery, liposomes can be formulated as a suspension, aerosol, cream, gel 
or dry powder for topical or parenteral administration (Lasic, 1998; Storm and 
Crommelin, 1998).  The mechanisms of biodistribution and in vivo distribution of 
liposome formulations vary depending on physicochemical properties such as lipid 
composition, size, encapsulation efficiency as well as degree of surface hydration 
(Lian and Ho, 2001).  There are 4 major interactions between liposomes and cells.  
Lipid exchange is an interaction that involves exchange of liposomal lipids for lipids 
of the cell membrane.  This mechanism of interaction may lead to premature leakage 
of the entrapped agent resulting in sub-optimal therapeutic responses (Lasic, 1998; 
Lian and Ho, 2001).  The second mode of interaction involves liposome adsorption 
onto the lipid membrane.  Adsorption is usually followed by endocytosis or fusion.  
Endocytosis delivers the liposome and its contents into the cytoplasm via a 
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lysosymal vacuole in which the low lysosymal pH and enzymes may inactivate the 
encapsulated drug, leading to loss of activity (Lasic, 1998; Lian and Ho, 2001).  
Fusion delivers the liposome directly into the cell.  After fusion with the endovacuolar 
membrane, liposome contents are released into the cytoplasm (Lasic, 1998; 
Torchilin, 2005).    
The benefits of liposomal encapsulation, which include reduced toxicity, and/or 
increased efficacy are due to improved retention of the entrapped drug at the site of 
action, have fuelled the development of many antifungal  and anticancer liposome 
formulations; many of which have received regulatory approval and have shown 
significant therapeutic utility (Zhigaltsev, 2008).  Listed in Table 7 are some of the 
nanomedicine products currently on the market (Bawarski et al., 2008). 
 
Table 7: Nanomedicine products currently on the market (Bawarski et al., 2008) 
Product Drug Formulation  Application 
Doxil Doxorubicin Liposome Kaposi‘s sarcoma in AIDS 
Amphocil Amphotericin B  Lipocomplex Serious fungal infections 
Ambisome Amphotericin B Liposome Serious fungal infections 
DaunoXome Daunorubicin citrate Liposome Kaposi‘s sarcoma in AIDS 
Abelecet Amphotericin B Lipid complex Serious fungal infections 
Rapamune Sirolimus Nanocrystal particles Immunosuppressant 
Emend Aprepitant Nanocrystal particles For chemotherapy to delay 
nausea and vomiting 
TriCor Fenofibrate Nanocrystal particles Primary 
hypercholesterolemia, 
mixed lipidemia, 
hypertriglyceridemia.   
Megace ES Megestrol acetate Nanocrystal particles Treatment of anorexia, 
cachexia, or an unexplained 
significant weight loss in 
patients with a diagnosis of 
AIDS 
Abraxane Paclitaxel Albumin-bound 
nanoparticles 
Metastatic breast cancer 
Elestrin Estradiol Calcium 
phosphate–based 
nanoparticles 
Treatment of moderate-to-
severe vasomotor 
symptoms (hot flashes) 
in menopausal women 
 
Liposomes are a family of vesicular structures differing widely in their characteristics. 
Liposome formulations of various drugs can be optimized in terms of drug content, 
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stability, biodistribution patterns and cellular uptake by modifying their 
physicochemical properties (Sharma and Sharma, 1997).  These parameters include 
fluidity of the bilayer membrane, surface charge and density as well as size. 
 
a) Bilayer fluidity 
The phospholipid from which a particular vesicle is made determines the stiffness 
and permeability of the membrane bilayer (Storm and Crommelin, 1998).  
Phospholipids have characteristic phase transition temperatures and can be found in 
different physical states above and below this temperature (Sharma and Sharma, 
1997).  The temperature at which the different phases are in equilibrium is termed 
the transition temperature (Tc), and is generally dependent on the nature and length 
of the phospholipid hydrocarbon chain.  Phospholipids with long chains have a 
higher Tc than those with shorter chains   (Taylor and Morris, 1995; Lasic, 1998; 
Storm and Crommelin, 1998).  
Phospholipids exist in one of two states: at low temperatures, a solid-gel state which 
is highly ordered predominates and at higher temperatures a crystalline state, which 
is highly disordered is more dominant (Sharma and Sharma, 1997).  At low 
temperatures, the lipid molecules do not show much lateral motion, the carbon 
atoms in the hydrocarbon chain are in a trans conformation leading to a closely 
packed structure.  With an increase in temperature, the lipids move into the 
crystalline phase and the cis conformation predominates.  This leads to the formation 
of kinks in the hydrocarbon chain resulting in loss of structural rigidity and a fluid 
membrane.  The phase behaviour of liposomes determines permeability, protein 
binding and to some degree, fusion of liposomes (Lian and Ho, 2001).     
 
b) Size and surface charge and density  
Particle size and distribution of liposomes in a colloidal system determine the in vivo 
distribution, biological fate, toxicity, and targeting ability of these delivery systems. In 
addition, they can influence drug loading, drug release, and stability of these 
systems.  The smaller the particles, the larger the surface area to which the drug is 
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exposed and the quicker the drug release.  This is because the drug is concentrated 
near or at the surface of the vesicle, leading to faster drug release (Singh and Lillard, 
2009).  Conversely, larger particles have a larger core, therefore more drug is inside 
the liposome, and the release will be slower.  Small particles are, however 
associated with a higher incidence of aggregation.  Thus, it is evident that control of 
particle size is important (Singh and Lillard, 2009).  
It often happens that electrical charges develop, by several mechanisms, at the 
boundary between particles of the dispersed phase and the aqueous medium 
(Elimelech et al., 1994; Werling et al., 2008).  These charges play an important role 
in determining the interaction between the particles of the dispersed phase and the 
resultant physical stability of the system. For liposomes and other disperse systems, 
the in vivo fate is affected by these surface charges (Kovalchuk et al., 2009).  The 
presence of these charges causes an uneven distribution of ions surrounding the 
particle and the development of an electric potential between the surface of the 
particle and the electrically neutral bulk solution of the system (Delgado et al., 2007).   
The electric potential between a stationary fluid layer enveloping the particle and the 
bulk solution phase can be determined by measuring the mobility of the particle in an 
applied electric field. The particle does not move in this applied field on its own but it 
carries a thin layer of ions and solvent around it.  The surface separating the 
stationary medium from the mobile particle and its bound ions and solvent is called 
the surface of hydrodynamic shear.  The zeta potential is the potential at this surface 
(Delgado et al., 2007).   
Zeta potential serves as an important parameter in characterizing the electrostatic 
interaction between particles in a dispersed system and the properties of the 
dispersion as affected by this electrical phenomenon. The stability of a colloidal 
dispersion is therefore due to a balance between attractive and repulsive forces 
within the system.   If the zeta potential drops below a certain level, the particles in 
the system will aggregate because of the difference in distribution of electrical 
charges.  Conversely, a high zeta potential retains the stability of the disperse 
system (Singh and Lillard, 2009).   
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Because liposome formulations differ in physicochemical properties due to 
membrane fluidity (which is a function of the constituent lipids and their molar ratios 
in the formulation), surface charge, as well as size, they can be optimized in terms of 
drug content (percent encapsulation) and cellular uptake or biological activity by 
modifying these parameters (Sharma and Sharma, 1997).  
 
There are 2 ways in which one can investigate the combination of these parameters 
that would yield liposome formulations with maximized biological activity and drug 
content: The effect of each of the variables is studied independently while the others 
are held constant.  The pitfall of this method is that it is time-consuming and may 
lead to inaccurate results, as it cannot quantitatively explore the influence of 
combined factor effects on the response (Li et al., 2007).  The other method is 
response surface methodology (RSM).    
 
 
2.7 Response surface methodology  
 
Experiments with two or more factors are encountered frequently.  The best way to 
carry out such experiments is by using factorial experiments. A factorial experiment 
is one whose design consists of two or more factors that can be combined in any 
number of ways, known as levels, to investigate the combination that yields the best 
possible outcome or response (Hendricks et al., 1996; Myers et al., 2009).  A 
factorial design is one that allows the studying of the effect of each factor on the 
response variable, as well as the effects of the interactions between the two factors 
on the response variable.  It therefore becomes important to determine the operating 
parameters at which a particular response reaches its optimum.  The optimum can 
either be a minimum or a maximum of a function of the design parameters (Myers et 
al., 2009).  Phospholipid and cholesterol content were identified as the most 
important parameters and percent encapsulation and bacterial inhibition, the 
response or dependent variables. 
Response surface methodology (RSM) is a collection of statistical and mathematical 
techniques useful for developing, improving and optimizing processes in which a 
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response of interest is influenced by several variables and the objective is to 
optimize this response (Myers et al., 2009).  RSM also quantifies the relationships 
between the controllable input parameters and the obtained response surfaces.  The 
design procedure in RSM is as follows: 
 A series of experiments are conducted for adequate and reliable 
measurement of the response of interest 
 Development of a mathematical model of the second order response surface 
with the best fit 
 Determining the optimal set of conditions or experimental parameters that 
produce the minimum or maximum response 
 Representing the direct and interactive effects of the process parameters 
through two and three dimensional (3-D) plots (Akram, 2002).  
 
Because the first requirement for RSM involves the design of experiments to achieve 
adequate and reliable measurement of the response of interest, an appropriate 
mathematical design technique needs to be employed.  To meet this requirement, an 
appropriate experimental design technique has to be employed. The experimental 
design techniques commonly used for process analysis and modelling are the full 
factorial, partial factorial and central composite rotatable designs (Aslan, 2008). 
 
Central composite design (CCD) is the most widely used response surface design.  
CCD is an experimental design process in which a multi-level factorial or fractional 
factorial is chosen to allow the estimation of all first-order and factor interaction 
terms, augmented with further points which also allow polynomial effects to be 
estimated (Myers et al., 2009).  The practical application of CCD arises through 
sequential experimentation.  It consists of a 2k factorial design, augmented with 2k 
axial points and nc centre points. The axial points are chosen such that they allow 
rotatability, which ensures that the variance of the model prediction is constant at all 
points equidistant from the design centre. Replicates of the test at the centre are 
very important as they provide an independent estimate of the experimental error. 
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If for example there are 5 levels for each of 3 factors, a (53) factorial design, there 
are 125 possible treatment combinations.  The corresponding CCD has only (nf + na 
+ nc = 8 + 6 + 1 = 15) treatment combinations or design points where nf is the 
number of factorial points, na the number of axial points and nc the number of centre 
points.  CCD eliminates the need for a large number of treatment combinations, 
while retaining the essential design points (Akram, 2002).  Once the desired ranges 
of values are determined, they are coded to lie at ± 1 for the factorial points, 0 for the 
centre points and ± 1 for the axial points.  The codes are calculated as functions of 
the range of interest of each factor as shown in Table 8. 
Table 8: Relationship between coded and actual values of a variable 
Code Actual value of variable 
-α Xmin 
-1 ({xmax + xmin}/2) – ({xmax – xmin}/2α) 
0 (xmax + xmin)/2 
+ 1 ({xmax + xmin}/2) + ({xmax – xmin}/2α) 
+α Xmax 
 
When the response data are obtained from the test work, a regression analysis is 
carried out to determine the co-efficients of the response model (b1, b2, b3,......., bn), 
their standard errors and significance.   
In addition to the constant (b0) and the error (ε) terms, the response model includes: 
i. Linear terms in each of the variables (x1, x2, x3,......., xn) 
ii. Squared terms in each of the variables (x1
2, x2
2, x3
2, ......, xn
2) 
iii. 1st order interaction terms (x1x2, x1x3........, xn –ixn) 
For the two variables in this study (cholesterol content and phospholipid 
composition), the general form of the second degree polynomial equation was: 
Y = (b0 + ε) + ∑bixj + ∑bijx
2 + ∑bijxixj 
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CHAPTER 3 
METHODOLOGY 
 
3.1 Materials and chemicals 
 
1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC) and 1,2-Distearoyl-sn-
Glycero-3-Phosphatidylcholine (DSPC)  were purchased from Avanti Polar Lipids 
(Alabaster, AL, USA) while cholesterol was purchased from Northern Lipids 
(Barnaby, BC, Canada). Amoxicillin, chloramphenicol, Mueller-Hinton broth and MTT 
or [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide] were purchased 
from Sigma-Aldrich (St Louis, MO, USA). Cyclo(Tyr-Pro) was purchased from 
Bachem (Bubendorf, Switzerland). HPLC solutions were purchased from Merck 
(Darmstadt, Germany).   All other chemicals and reagents were obtained from local 
suppliers and were of analytical grade. 
 
3.2 Experimental design 
 
The two factors that were varied were phospholipid composition; which consisted of 
DMPC and DSPC; and cholesterol content.  A central composite rotatable design 
(CCRD) was chosen as the experimental design for finding out the exact quantitative 
relationship between the response (percent bacterial inhibition and percent 
encapsulation) and the input variables.  CCRD is an efficient and proven design, 
especially for two factors.  The number of runs required for a CCRD include the 
standard 2k factorial with its origin at the centre, 2k points fixed axially at a distance, 
say α, from the centre to generate the quadratic terms and replicate tests at the 
centre, where k is the number of variables.  The experimental region extended from 
– 1.414 to + 1.414 in terms of coded levels of independent variables, and α was 
chosen as 1.414.  To maintain rotatability, the α-value depends on the number of 
experimental runs in the factorial portion of the CCD: α = [number of factorial runs]1/4 
(Hendricks et al., 1996)  
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In this study, two factors were varied.  Therefore:  
Runs in factorial portion = 22 
α = 22/4 
= 1.414    
Response surface methods are designs and models used for working with 
continuous treatments when describing the response goal.  The first goal is to 
optimize the response.  When there is more than one response, it is important to find 
the compromise optimum that does not optimize only one response.  The second 
goal is to understand how the response changes in a given direction by adjusting the 
design variables.  In general, the response can be visualized graphically. The graph 
is helpful to see the shape of a response surface.  Hence the function f(X1 * X2) can 
be plotted against the levels of X1 and X2, as shown in Figure 13 (Bradley, 2007; 
Shih et al., 2008). 
20.00  
26.00  
32.00  
38.00  
44.00  
50.00  
56.00  
62.00  
68.00  
74.00  
80.00    20.00
  25.00
  30.00
  35.00
  40.00
0  
0.2  
0.4  
0.6  
0.8  
1  
  
S
td
E
rr
 o
f 
D
e
s
ig
n
  
  A: Phospholipid  
  B: Cholesterol Content  
 
Figure 13: Response surface plot 
 
In this graph, each value of X1 and X2 generates a y-value. This three-dimensional 
graph shows the response surface from the side and it is called a response surface 
plot.  The red dots represent the coordinates of the design points which range from – 
α to + α.  The design is rotatable which means that all the points in the design area 
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are at equal distance from the centre. This leads to distribution of errors among all 
points equally (Bradley, 2007).  
 
In order to obtain the required data, the ranges of values for the two variables were 
defined according to previous experiments as follows: Cholesterol content of 16 – 44 
% and a phospholipid composition of 7.6 – 92 %.  Applying the relationships in Table 
8, the values of the codes were calculated as shown in Table 9.  These were then 
used to determine the actual levels of the variables for each of the 13 experiments 
(Table 10).   
 
Table 9: Coded and actual levels for independent factors used in the experimental design 
Independent variables Levels 
 -1.414 
- α 
-1 0 +1 +1.414 
+ α 
Phospholipid (mg) 7.6 20 50 80 92 
Cholesterol  (mg) 16 20 30 40 44 
 
3.3 Experimental procedures 
3.3.1 Preparation of liposome encapsulated cyclo(Tyr-Pro) 
 
Liposomes were prepared from a mixture of DMPC, DSPC and cholesterol by the 
thin-film hydration method (Lasic, 1997).  The general elements of this procedure 
involve preparation of the lipid for hydration, hydration with agitation and finally size 
reduction to a uniform distribution of vesicles, as illustrated in Figure 14 below.  
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Figure 14: Preparation of liposomes by thin-film hydration (Lasic, 1997) 
 
The lipid compositions of the various liposomes used in the experiment are provided 
in Table 10.  Appropriate amounts of the lipids (DMPC, DSPC and cholesterol) were 
dissolved in 5 ml of a 4:1 mixture of cholesterol and methanol in a 50 ml round-
bottom flask.     The percentage of A as seen in Table 10 below represents the molar 
portion of DMPC in the formulation and the remainder is that of DSPC, and B 
represents the molar amount of cholesterol, and were calculated as follows: 
Run nr 1 (from table below): For the cholesterol component: 
60 mg * 0.20 = 12 mg (mass used in formulation) 
For the phospholipid component 
60 mg – 12 mg = 48 mg (mass of DMPC and DSPC combined) 
DMPC: 48 mg * 0.80 = 38.4 mg; DSPC: 48 mg – 38.4 mg = 9.6 mg  
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Table 10: Central composite design consisting of experiments for the study of two experimental 
factors in actual levels 
Run # Phospholid 
component 
(A) (%) 
Cholesterol 
component 
(B) (%) 
Mass of 
cholesterol 
(mg) 
Mass of 
DMPC    
(mg) 
Mass of 
DSPC   
(mg) 
1 80 30 18 33.6 8.4 
2 50 30 18  21 21 
3 50 30 18   21 21 
4 92 30 18 37.8 4.2 
5 20 40 24  7.2 28.8 
6 20 20 12  9.6  38.4 
7 50 44 26.4  16.8 16.8 
8 50 30 18 21  21 
9 50 30 18  21 21 
10 7.6 30 18  3.2 38.8 
11 50 30 18  21 21 
12 50 16 9.6 22  22 
13 80 40 24  28.8 7.2 
 
The respective lipid mixtures were dried on a rotary evaporator (Buchi R210, Flawil, 
Switzerland) at 60 °C in a heating bath (Buchi B495, Flawil, Switzerland) under 
controlled vacuum for three hours.  A thin, dry film of lipid was deposited on the inner 
wall of the flask.  Nitrogen gas was then flushed through the flasks to remove all 
traces of chloroform.  The dry lipid films, containing 60 mg of total lipid, were 
subsequently hydrated with 5 ml of a 10 mg/ml solution of cyclo(Tyr-Pro) dissolved in 
reverse osmosis (RO) water with DMSO 5 % v/v.  The CDP mixtures were shaken 
on a shaking water bath for three hours at 60 °C to allow hydration of the lipid film.  
The temperature was kept above 60 °C, which is higher than the Tc of both DMPC 
and DSPC; both phospholipids were therefore in their more fluid phase, which 
coupled with adequate agitation, facilitated hydration. The product of hydration is a 
large, multilamellar vesicle (MLV) comparable in structure to an onion, with each lipid 
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bilayer separated by an aqueous layer. This was followed by extrusion of the MLVs.  
Extrusion is a technique in which a lipid suspension is forced through a 
polycarbonate filter with a defined pore size in order to yield particles having a 
diameter near the pore size of the filter used.  The various liposome suspensions 
were extruded 15 times through a  100 nm pore size Whatman Cyclopore Track 
etched membrane using a mini extruder (Avanti Polar Lipids, Alabaster, USA) 
(Rukholm et al., 2006; Pradhan et al., 2007).  The liposome suspensions were stored 
at 4 °C until further use. 
 
3.3.2 Characterization of liposome formulations  
 
Liposomes are formulated by different methods and, as a result may have different 
pharmacokinetic properties.  This difference may have an impact on their in vivo and 
in vitro behaviours (Storm and Crommelin, 1998).  Liposomes can be characterized 
in terms of their chemical, physical and biological properties.  Physical 
characterization evaluates the size and size distribution, morphology, electric 
potential and encapsulation efficiency of liposome vesicles whilst chemical 
characterization evaluates phospholipid concentration, pH, cholesterol autooxidation 
and phospholipid hydrolysis (Storm and Crommelin, 1998; Samad et al., 2007).  
 
3.3.2.1 Evaluation of phospholipid concentration: Stewart assay 
 
Phospholipid concentration of the final liposome formulations was measured using 
the Stewart assay. This assay makes use of the ability of phospholipids to form a 
complex with ammonium ferrothiocyanate in organic solution.  The presence of 
inorganic phosphate does not interfere with the assay.   A simple conversion factor is 
then used to interpret absorbance values into milligrams of phospholipid.  This 
conversion factor is affected by the different head groups of the various 
phospholipids.  The Stewart assay can thus not be employed to samples where 
mixtures of unknown phospholipids may be present (Lasch et al., 2003). 
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The ammonium ferrothiocyanate solution was prepared by mixing 27.03 g of ferric 
chloride with 30.4 g ammonium thiocyanate and making it up to a volume of 1000 ml 
with reverse osmosis water. A standard sample containing 0.2 mg/ml of phospholipid 
was prepared in 15 ml centrifuge tubes as shown in Table 11. 
 
Table 11: Stewart assay for phospholipid quantitation 
Tube number Standard (ml) Chloroform (ml) Ferrothiocyanate (ml) 
0 0.0 2.0 2.0 
1 0.1 1.9 2.0 
2 0.2 1.8 2.0 
3 0.4 1.6 2.0 
4 0.6 1.4 2.0 
5 0.8 1.2 2.0 
6 1.0 1.0 2.0 
 
The tubes were vortexed for 30 seconds after which they were centrifuged at 3000 
rpm (Lasec Hermle 2300, Wehingen, Germany) for 5 minutes.  On separation, the 
lower chloroform phase was aspirated and discarded, and the optical density of the 
chloroform phase measured at 485 nm on a spectrophotometer (Lasec Cecil LE 
2021 Wehingen, Germany).   
A standard curve was constructed by plotting the absorbance of the phospholipid 
complex at 485 nm versus the final concentrations of the standard solutions, which 
ranged from 0.095 mg/ml to 0.06 mg/ml, and a linear regression trendline was fitted 
to the plot (Microsoft Excel® 2007, Microsoft Corporation) and is illustrated in Figure 
15 below.  Each of the standards was analyzed in triplicate.   
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Figure 15: Calibration curve constructed by plotting the absorbance of the ferrothiocyante-
phospholipid complex at 485 nm vs concentration of cholesterol in test samples.  Linear regression 
equation: y = 10.155x – 0.0431, R
2 
= 0.9985 
 
Linearity of an analytical procedure is its ability, within a given range, to obtain test 
results that are directly proportional to the concentration of analyte in the sample 
(ICH Harmonized Tripartite Guideline Q2B, 1994).  The requirements for linearity are 
that the correlation coefficient of the regression line is greater than or equal to 0.999 
and that the y-intercept is not significantly different to zero.  Significance of the y-
intercept was assessed by expressing the y-intercept as a percentage of detector 
response (mean peak area) at the 100 % analyte level as follows: 
Assessment value (z) = y-intercept/100 % detector response * 100  
The y-intercept is accepted as not significantly different from zero if the assessment 
value (z) falls within the specified limit of 2 > z > -2.   
The requirements for linearity were met since the correlation coefficient of the 
regression line was found to be equal to 0.9985.  Significance of the y-intercept was 
calculated according to the following equation as follows: 
  Assessment value (z) =  - 0.0431/0.580 * 100 
        = - 7.43 % 
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To obtain the phospholipid content of the unknown samples, a 25 µl aliquot of each 
of the 13 lipid suspensions was mixed with 1975 µl of chloroform and 2 ml of 
ferrothiocyanate and analyzed as described above. The concentrations were 
determined using the linear equation derived from the standard curve as follows:   
For unknown nr 1: 
Absorbance @ 485 nm = 0.742 
Linear equation: y = 10.15x – 0.0431 (substitute the y in the equation with 
absorbance @ 485 nm for the unknown samples and solve for x) 
Therefore:   0.742 = 10.15x – 0.0431 
      X    = 0.0773 mg/ml 
A 25 µl aliquot of the unknown sample was diluted in 1975 µl of chloroform, making 
the final volume of the sample 2000 µl; the actual concentration of phospholipid in 
the sample was therefore: 
0.0773 mg/ml / 25 * 2000 = 6.184 mg/ml 
 
3.3.2.2 Particle size analysis and measurement of zeta potential 
 
In order to assess the physical stability and particle size of the liposome, samples 
were analyzed by a Zetasizer Nano ZS instrument (Malvern Instruments (Pty) Ltd., 
Worcestershire, UK) at 25 ˚C. All samples for particle sizing and zeta potential were 
prepared in the same manner, where each sample was diluted 1 in 10 (v/v) with 
deionized water or PBS buffer pH 7.4, and passed through a membrane filter (0.22 
µm, Millipore Corp., Bedford, MA, USA). Measurements were done in different 
disposable capillary cuvettes for zeta potential and quartz cuvettes for particle size 
analysis. All sample measurements were done in triplicate, with multiple iterations for 
each run in order to elute size intensity and zeta potential distribution profiles over 
time.  
 
  
53 
 
3.3.2.3 HPLC method development 
 
High performance liquid chromatography (HPLC) is a type of chromatography used 
to separate and purify products of chemical reactions and can detect proteins, 
nucleic acids, pigments, vitamins, some steroids and amino acids (McMurry, 2000).  
It makes use of a liquid mobile phase and a very finely divided uniformly packed 
stationary phase, ensuring a larger surface area for better adsorption (Skoog et al., 
1996).  High pressure pumps are required to force solvent through the tightly packed 
HPLC column (McMurry, 2000) and electronic detectors such as UV, conductivity 
and fluorescence are used for monitoring the appearance of material eluting from the 
column.   
HPLC analyses were performed on cyclo(Tyr-Pro) using the Shimadzu® LC2020 
System (Kyoto, Japan), which is made up by the following: SPD M20A Photodiode 
Array (PDA) detector; S/L 20A autosampler; DGU 20A5 degasser; CTO 10AS VP 
column oven and a LC 20AB liquid chromatogram.  The HPLC apparatus was fitted 
with a Phenomenex® Luna C8 HPLC 5 μm spherical column, with dimensions 15 cm 
x 4.6 mm and the oven temperature was set at 40 ºC.  The chromatographic mobile 
phase consisted of 12 % v/v HPLC grade acetonitrile and 88 % v/v reverse osmosis 
water.  10 µl samples were injected onto the HPLC column and run at a flow rate of 
1.0 ml/min.  The PDA detector was observed at a wavelength of 220 nm.   Cyclo(Tyr-
Pro) was made up to a stock concentration of 0.597 mg/ml. This was prepared by 
dissolving 3.584 mg of cyclo(Tyr-Pro) in 0.3 ml of DMSO and was made up to 6 ml 
with RO water such that the final DMSO concentration was 5 % v/v.   This solution 
was then serially diluted to test concentrations of 0.299, 0.149, 0.0747 and 0.0373 
mg/ml. CDP solutions were all filtered through 0.45 µm PVDF membrane filters 
(Millex ® Syringe Driven Filter Units, Millipore Corporation, Bedford, USA).  This was 
done to remove any particles from the CDP solutions which might affect the integrity 
of the HPLC column.  Three replicate injections of each of the standards were 
performed. The data was collected and processed on LC Solution version 1.0.0.1.  A 
calibration curve for cyclo(Tyr-Pro) was constructed by plotting the peak areas of 
cyclo(Tyr-Pro) versus the respective concentrations, and a linear regression 
trendline was fitted to the plot (Figure 16).  Linearity of the standard curve was 
  
54 
 
determined and a linear correlation coefficient (R2) of 0.999 was defined as linear. 
The significance of the y-intercept was found to be 1.175 %.  The linearity 
requirements were met, since the correlation coefficient was equal to 0.999 (linear 
regression equation: y = 184.22x + 0.0616); and the y-intercept was not significantly 
different to zero.   
 
 
Figure 16: HPLC calibration plot constructed by plotting the mean peak area at 220 nm versus 
concentration of replicate samples of cyclo(Tyr-Pro) standards. Linear regression equation: y = 
184.22x + 0.0616, R
2
 = 0.999 
 
The external standard method is the most widely used method for the determination 
of the concentration in an unknown sample.  It involves the construction of a 
calibration curve using external standards of the analyte.  A fixed volume of each 
standard solution of known concentration is injected into the column and the peak 
response of each injection is plotted against the concentration of the standard 
solution.  The standards are called ‗external standards‘ because they are prepared 
and analyzed separately from the unknown samples.  After constructing the 
calibration plot, the unknown sample is prepared, injected and analyzed in exactly 
the same way.  The concentration of the analyte in the unknown sample is then 
determined from the calibration plot (Wang, 2001).  
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Specificity of a chromatographic method is the ability of the method to accurately 
measure the response of the analyte in the presence of all sample components 
(Green, 1996).  In HPLC, specificity suggests that a given analyte peak is indeed the 
desired compound and is 100 % pure (Krull and Swartz, 2001).  Peak purity 
analyses are performed by a photodiode array (PDA) detector to identify the 
presence of any co-eluting impurities.   
The PDA detector is an advanced type of UV detector.  PDA detectors provide 3-D 
information that allows accurate assessment of peak identity, purity and quantitation 
in a single run.   Depending on the wavelength, a tungsten lamp and a deuterium 
lamp are used as light sources.  The detector that was used in this study is the SPD-
20A UV-VIS detector, capable of measuring the absorbance spectrum from 190 – 
700 nm. The polychromatic light beam is focused on a flow-cell and subsequently 
dispersed by a holographic grating or quartz prism. The spectral light then reaches a 
chip that contains 100 to 1000 light-sensitive diodes arranged side by side. Each 
diode only registers a well-defined fraction of the information and in this way all 
wavelengths are measured at the same time.  When no significant spectral 
differences are found within a peak, one can conclude that the peak is spectrally 
homogenous and contains a single compound. 
 
Furthermore, a peak should be symmetrical in shape.  A peak is labelled as tailing or 
asymmetrical when it deviates from the ideal, symmetrical shape of a Gaussian 
peak.  The later eluted half of the peak is wider than the front half and the 
broadening appears to be emphasized near the baseline.  Peak tailing is measured 
using the United States Pharmacopoeia (USP) tailing factor (Tf) (Dolan, 2003).  The 
tailing factor is illustrated in Figure 17 and is expressed by the following equation: 
 
Tf = (a + b)/2a  
 
Where Tf = tailing factor; a = the front half-width measured at 5 % of peak height; b = 
the back half-width measured at 5 % peak height.   
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Figure 17: Measurement of tailing using the USP tailing factor (Tf) (Adapted from Dolan, 2003) 
 
The chromatogram for cyclo(Tyr-Pro) is shown in Figure 18.  The chromatogram was 
assessed for the presence of compounds that might interfere or co-elute with the 
cyclo(Tyr-Pro) peak. The curve was smooth with no visible tailing, evident in the 
even Gaussian distribution of the curve. The chromatogram was assessed for the 
presence of compounds that might interfere or co-elute with the cyclo(Tyr-Pro) peak.  
Figure 19 is a representation of the peak purity curve.  It can be clearly seen from 
the smooth curve in Figure 19 that the sample tested was free from any impurities.   
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Figure 18: Representative HPLC spectrum for cyclo(Tyr-Pro) (tR = 5.2 ± 0.1 min) at a UV detection 
wavelength of 220 nm  
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Figure 19: Peak purity curve for cyclo(Tyr-Pro) measured over the wavelength range 190 – 700 nm, 
Peak purity index = 0.99999; single point threshold = 0.999951 
 
3.3.2.4 Characterization of encapsulation efficiency 
 
Encapsulation efficiency is a measurement of the fraction of total compound 
entrapped within a liposome.  Many of the techniques used for determining liposome 
encapsulation efficiency rely on destruction of the lipid bilayer with subsequent 
measurement of the released material.  The breakdown of the bilayer is achieved by 
dilution of the liposome suspension with alcohols such as 2-propanol, ethanol or 
methanol; extraction of lipids into chloroform or surfactant-induced bilayer disruption 
(Edwards and Baeumner, 2006). Other authors define encapsulation efficiency as 
the molar amount of encapsulated drug per mole of lipid, which is obtained by 
dividing the concentration of encapsulant by the concentration of the lipid (Kallinteri 
et al., 2004).  
  
58 
 
Quantification of liposomal cyclo(Tyr-Pro) was performed by HPLC analysis.  
Unencapsulated cyclo(Tyr-Pro) from each of the liposome formulations, was 
removed by centrifugation of the liposome suspensions at 13 500 rpm for 3 hours.  
The resultant supernatant was aspirated and discarded, and the pellet re-suspended 
in an equal volume of PBS (pH 7.4). This was followed by liposome membrane lysis 
by adding 100 µl of a 10 % Triton X-100 solution to 100 µl of each liposome 
suspension in a 1500 µl centrifuge tube, with subsequent incubation at 60 °C for 60 
minutes to facilitate membrane breakdown.    The resultant solutions were made up 
to 1000 µl with PBS (pH 7.4) and then vortexed for 30 seconds.  Subsequently, the 
solutions were filtered through 0.45 µm membrane filters prior to HPLC analysis.  
HPLC analyses were performed as outlined in Section 3.3.2.3 above.  Unknown 
concentrations were calculated based on a standard concentration of cyclo(Tyr-Pro) 
that was prepared (0.597 mg/ml).  Encapsulation efficiency was calculated as the 
percentage of cyclo(Tyr-Pro) incorporated inside the liposome relative to the initial 
amount in drug solution (10 mg/ml) (Omri et al., 2002). 
 
3.4 Antibacterial activity of liposomal cyclo(Tyr-Pro) 
 
Antimicrobial agents are used to control microorganisms by either killing an organism 
or retarding its growth.  An antimicrobial agent can only be effective if it influences 
some vital part of the microbial cell.  Parts of the cell most vulnerable to the action of 
antibiotics are the protoplasmic membrane, certain enzymes, the nucleus or protein 
structures such as those found in the cell wall (Volk and Wheeler, 1969).  The choice 
of antimicrobial agent depends not only on the type of pathogenic organism but on a 
number of other factors such as co-morbid disease states, age, pregnancy and cost 
of the antimicrobial agent (Katzung, 2007).  The fundamental variances in bacteria 
may possibly account for the fact that certain agents are effective against one type of 
organism and not another (Volk and Wheeler, 1969).  In order to assess its 
antibacterial activity, cyclo(Tyr-Pro) was tested against Gram-positive 
Staphylococcus aureus and Bacillus cereus as well as the Gram-negative 
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Escherichia coli and Pseudomonas aeruginosa, which were selected based on their 
pathogenicity, being the causative organisms of a wide variety of infectious diseases. 
 
A) Staphylococcus aureus 
 
Staphylococci are spherical Gram-positive bacteria that resemble grapes in shape.  
S. aureus may occur as a commensal on skin as well as the microflora of the upper 
respiratory tract, intestine, vagina and oral cavity (Baumann, 2007).  A variety of 
toxins such as cytolytic toxins, exfoliative toxins A and B, toxic shock syndrome 
(TSS) toxin and enzymes such as cell-free coagulase, hyaluronidase and beta-
lactamases make it possible for some strains of S. aureus to invade the body and 
cause diseases such as bacteremia, pneumonia, wound infections, food poisoning, 
TSS, diseases of joints, bones and blood (Baumann, 2007).   
 
B) Bacillus cereus 
 
Bacillus cereus is a rod-shaped Gram-positive bacterium.  It is responsible for a 
small number of food-bourne illnesses; causing severe nausea, vomiting and 
diarrhoea.  The food-bourne illnesses occur due to survival of bacterial endospores 
when food is improperly cooked (Baumann, 2007).   
 
C)  Escherichia coli 
 
E. coli forms part of a large group of bacteria called Enterobacteriaceae.  It is a rod-
shaped, facultatively anaerobic Gram-negative bacterium.  E. coli is an inhabitant of 
the human gastro-intestinal tract.  It is responsible for many different kinds of 
infection including septicaemia, urinary tract infections, neonatal meningitis and 
gastritis; which are all mediated by exotoxins called enterotoxins (Baumann, 2007).   
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D) Pseudomonas aeruginosa 
 
P. aeruginosa is a Gram-negative aerobic rod belonging to the family 
Pseudomonadaceae.  It is commonly found in soil and water, rarely in human 
microflora.  It is an opportunistic pathogen that typically infects immunocompromised 
individuals.  P. aeruginosa typically infects the respiratory tract, urinary tract, burns 
and wounds especially in neutropenic patients, cancer patients, burn victims and 
those with cystic fibrosis (Baumann, 2007). 
 
3.5 Preparations of test solution 
3.5.1 Liposomal cyclo(Tyr-Pro) 
 
Liposomal cyclo(Tyr-Pro) was prepared as outlined in section 3.3 above.  
  
3.5.2 Negative control 
 
A negative control representing 100 % viability of test organism growth was 
necessary in order to compare test organism growth in the presence of drug 
solutions.  This negative control consisted of DMPC/DSPC liposomes encapsulating 
5 ml of saline water and DMSO 5 % v/v. 
 
3.5.3 Positive control 
 
For Gram-positive organisms, amoxicillin was chosen as the control and prepared at 
1 mg/ml in RO water.  Amoxicillin is a beta-lactam antibiotic (Hugo and Russell, 
2004).  It acts by disrupting synthesis of the cell envelope in growing cells, 
inactivating penicillin-binding proteins and inhibiting the synthesis of peptidoglycan.  
Only growing cells can be killed by amoxicillin.  It has low activity towards Gram-
negative organisms owing to poor penetration of the outer membrane (Rang et al., 
2007).   
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For Gram-negative organisms, a 0.5 mg/ml solution of chloramphenicol in RO water 
was chosen as the control solution.  Chloramphenicol was first isolated from the 
actinomycete Streptomyces venezuelae, but can now be synthesized chemically.  It 
is bacteriostatic against Gram-positive and Gram-negative bacteria as well as 
mycoplasma, chlamydia and rickettsia (Hugo and Russell, 2004).  It acts by binding 
to the 50S ribosomal subunit to selectively inhibit transpeptidation in bacterial protein 
synthesis.  It is reserved for serious infections because of the associated adverse 
effects.  Its major toxicity on the haematopoietic system is through inhibition of 
mitochondrial protein synthesis.  It causes reversible bone marrow suppression and 
in extreme cases, irreversible aplastic anemia (Rang et al., 2007).   
The control solutions included DMSO 5 % v/v.  All solutions were filtered through a 
sterile 0.22 µm acetate filter into sterile eppendorf tubes and stored at 4 °C until 
further use.    
 
3.5.4 MTT dye solution 
 
Microbial growth in microplates is often measured as an increase in absorbance.  A 
growth indicator, the yellow tetrazolium salt MTT dye [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl-tetrazolium bromide] is added to facilitate the measurement of microbial 
cell viability.  This method is based on the tetrazolium salt MTT changing colour from 
its initial yellow colour in its oxidized state, to a purple colour when reduced by the 
metabolic activity of the microorganism in the mitochondria (Gabrielson et al., 2002).  
MTT forms non-water-soluble formazan crystals within the cells of the 
microorganisms.  The amount of these crystals is determined spectrophotometrically 
and therefore serves as an estimate for the number of mitochondria and hence 
number of living cells in a sample (Freimoser et al., 1999; Gabrielson et al., 2002).   
 
MTT was made up in reverse osmosis (RO) water to give a stock concentration of 
0.5 mg/ml.  The solution was then sterilized by filtration through a sterile 0.22 µm 
acetate filter and stored at 4 °C until further use.   
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3.6 Standardisation of bacterial cultures 
 
Test cultures included the Gram-positive Staphylococcus aureus and Bacillus cereus 
as well as the Gram-negative Escherichia coli and Pseudomonas aeruginosa, and 
were obtained from the Department of Biomedical Technology at the Nelson 
Mandela Metropolitan University.  The bacteria were chosen because of their 
classification as well as pathogenicity.   
 
Each test organism was prepared by scraping pure colonies off relevant agar plates 
with the aid of a flame sterilised platinum loop followed by inoculation into 20 ml 
sterile Meuller-Hinton broth.  The cultures were incubated overnight at 37 °C in an 
orbital shaker (Labcon Incubator Labotec (Pty) Ltd, SA) at 100 rpm for 24 hours.  
The overnight cultures were sub-cultured by transferring 100 µl of test organism into 
20 ml sterile Mueller-Hinton broth and incubating for 16 hours at 37 °C in an orbital 
shaker at 100 rpm.  Following that, the turbidity of the test cultures was measured at 
540 nm, using sterile Mueller-Hinton broth as a blank.  Absorbance values are listed 
in Table 12.  
 
 Table 12: Bacterial absorbance at 540 nm 
Bacterium Absorbance in nm 
Staphylococcus aureus 0.703 
Bacillus cereus 0.816 
Escerichia coli 0.704 
Pseudomonas aeruginosa 0.816 
 
The absorbance of each culture was adjusted to a reading of 0.22 absorbance units 
(AU) as follows: 
 
Staphylococcus aureus: 0.703 AU * X = 0.22 AU * 10 ml 
    Therefore X = 0.22 AU * 10 ml/0.703 AU 
      = 3.13 ml of standardised culture  
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This was made up to 10 ml using sterile Mueller-Hinton broth, and subsequently 
serially diluted to give test culture absorbance units of 0.11, 0.055 and 0.0275 
respectively.  
  
3.7 MTT linearity assay 
 
In order to establish whether the intensity of the formazan produced is proportional to 
the number of viable bacteria in a given sample, an MTT linearity assay was done on 
all the bacterial cultures.  A volume of 100 µl of the standard inocula and the 
respective serial dilutions were pipetted into a 96-well microplate with 100 µl MTT 
dye.  The microplates were incubated at 37 °C for 4 hours, followed by centrifugation 
(Eppendorf 5804R, Germany) at 3000 rpm for 7 minutes to pellet the insoluble 
formazan precipitate (Freimoser et al., 1999).  The supernatant was aspirated 
discarded and the precipitate dissolved by adding 100 µl of DMSO to each well.  
Absorbance was read at 540 nm.  Experiments were done in triplicate. 
 
A straight line graph was constructed by plotting the absorbance of MTT at 585 nm 
versus the number of colony forming units, and a linear regression trendline was 
fitted to the plot (Microsoft Excel® 2007, Microsoft Corporation).  A linear relationship 
(Figures 20 to 23) was found with all the organisms, as indicated by the linear 
correlation coefficient (R2), which is greater than 0.99, even though the y-intercepts 
were significantly different to zero.  The intensity of the MTT dye was found to be 
directly proportional to the number of viable bacteria.   
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Figure 20: Correlation between the absorbance of MTT measured at 540 nm and growth of Bacillus 
cereus. Results are expressed as the mean of triplicate determinations. Linear regression equation: y 
= 3.4001x + 1.0508; R
2
 = 0.9753 
 
 
Figure 21: Correlation between the absorbance of MTT measured at 540 nm and growth of 
Pesudomonas aeruginosa. Results are expressed as the mean of triplicate determinations. Linear 
regression equation: y = 4.1947 + 0.295; R
2
 = 0.9826  
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Figure 22: Correlation between the absorbance of MTT measured at 540 nm and growth of 
Escherichia coli. Results are expressed as the mean of triplicate determinations. Linear regression 
equation: y = 6.076x + 1.565; R
2
 = 0.993 
 
 
Figure 23: Correlation between the aborbance of MTT measured at 540 nm and growth of 
Staphylococcus aureus. Results are expressed as the mean of triplicate determinations. Linear 
regression equation: y = 4.079x + 0.7184, R
2
 = 0.9743  
 
3.8 Standardisation of colony numbers 
 
Further dilutions of each culture were made as follows: 
0.1 ml of standardised culture (0.22 AU) into 9.9 ml of sterile water → A 
0.1 ml of A into 9.9 ml of sterile water → B 
0.1 ml of B into 9.9 ml of sterile water → C 
0.1 ml of C into 9.9 ml of sterile water → D 
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0.1 ml of each dilution was subsequently plated onto sterile nutrient agar plates and 
the number of colony forming units (CFU) formed for each dilution was counted after 
a 16-hour incubation of the plates at 37 ºC.  Plating and counts were done in 
triplicate.  The number of organisms per millilitre of standardised culture was 
calculated as follows:  
 
Staphylococcus aureus: 
 
536 colonies present in 104 dilution 
5.36 * 106 CFU/0.1 ml = 3.1 * 107 CFU/ml 
Table 13 lists the volumes of standardised cultures required in 10 ml to obtain 5 x 
105 CFU/ml.   
 
Table 13: Volumes of cultures needed in 10 ml broth to get 5 x10
5 
CFU/ml 
Organism Volume of culture (µl) 
Staphylococcus aureus 93.3 
Bacillus cereus 130.2 
Escherichia coli 86.2 
Pseudomonas aeruginosa 74.4 
 
 
3.9 Antimicrobial assay 
3.9.1 Screening of liposomal formulations for bacterial inhibition 
 
After quantification of encapsulation, a screening test was conducted with all the 
cyclo(Tyr-Pro) suspensions to investigate the formulation which yielded the highest 
percent bacterial inhibition. The concentration of each of the suspensions was 
adjusted to the concentration of the formulation with the lowest encapsulation 
efficiency, which was 0.261 mg/ml.   50 µl of each of the test organisms was initially 
incubated at 37 °C for 20 hours with a 50 µl aliquot of each of the 13 formulations in 
a 96-well microplate, in an orbital shaker.  The negative control consisted of 
liposomes encapsulating saline water with 5 % DMSO.  The positive controls 
consisted of a 1 mg/ml solution of amoxicillin and a 0.5 mg/ml solution of 
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chloramphenicol for the Gram-positive and Gram-negative bacteria respectively.  
Both solutions were made up in saline water with 5 % v/v DMSO.  Non-encapsulated 
cyclo(Tyr-Pro) at a concentration of 20 mg/ml was included in the assay to validate 
its antibacterial activity.  After incubation, 50 µl of MTT dye (0.5 mg/ml) was added to 
each well.  The plates were again incubated at 37 °C for 60 minutes to allow for the 
metabolic reduction of MTT.  The plates were subsequently removed from the 
incubator and centrifuged at 3000 rpm (Eppendorf 5804R, Germany) for 7 minutes to 
pellet the insoluble formazan precipitate (Freimoser et al., 1999).  The supernatant in 
each of the wells was aspirated and discarded.  The formazan product present was 
dissolved in 100 µl of DMSO.  The microplates were read at 540 nm using a 
microplate reader (Biotek Powerwave XS).  Experiments were conducted in 
triplicate.  The results were reported (Table 20) as percentage inhibition of growth of 
each organism culture after 20 hours of exposure to cyclo(Tyr-Pro) and the positive 
control, relative to the negative control.  Percent inhibition was calculated as follows: 
 
Pseudomonas aeruginosa: 
 
Absorbance of bacterium with liposomal cyclo(Tyr-Pro):  2.62 
Absorbance of bacterium with negative control: 3.23 
Percent inhibition =  1 – (observed absorbance/absorbance of negative control) * 100 
= 1 – (2.62/3.23) * 100 
= 18.8 % 
 
3.9.2 Selection of optimum parameters for liposomal cyclo(Tyr-Pro) 
formulations 
 
In order to find out the level of each independent variable that yield a liposomal 
formulation with optimum properties in terms of percent bacterial inhibition and 
encapsulation against each of the bacteria, a simple search was done within the 
range of the CCD.  This was justifiable because the parameter range of the design is 
selected to include all possible concentrations of the independent variables.  The 
target parameters for each formulation are listed in Tables 14 to 17 below. 
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Table 14: Optimisation parameters for a liposomal formulation for Bacillus cereus 
Name Goal Lower limit Upper limit  Importance 
Phospholipid Is in range 0 100 3 
Cholesterol Is in range 0 50 3 
Encapsulation Maximise 2.61 5.36 3 
MIC Maximise 15.9 43.3 4 
 
Table 15: Optimisation parameters for a liposomal formulation for Escherichia coli 
Name Goal Lower limit Upper limit  Importance 
Phospholipid Is in range 0 100 3 
Cholesterol Is in range 0 50 3 
Encapsulation Maximise 2.61 5.36 3 
MIC Maximise 30 57.7 4 
 
 Table 16: Optimisation parameters for a liposomal formulation for Staphylococcus aureus 
Name Goal Lower limit Upper limit  Importance 
Phospholipid Is in range 0 100 3 
Cholesterol Is in range 0 50 3 
Encapsulation Maximise 2.61 5.36 3 
MIC Maximise 13.6 48 4 
 
Table 17: Optimisation parameters for a liposomal formulation for Pseudomonas aeruginosa 
Name Goal Lower limit Upper limit  Importance 
Phospholipid Is in range 0 100 3 
Cholesterol Is in range 0 50 3 
Encapsulation Maximise 2.61 5.36 3 
MIC Maximise 16 58 4 
 
 
These formulations were manufactured according to the thin-film method, as 
described in Section 3.3.  The lipid films were hydrated with 10 mg/ml of cyclo(Tyr-
Pro).  Phospholipid concentration, particle size and zeta potential, as well as 
characterization of encapsulation efficiency, were done according the methods 
discussed in Section 3.3.  
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3.9.3 Determination of minimum inhibitory concentration 
 
Minimum inhibitory concentration (MIC) is defined as the minimum concentration of 
an antibiotic that is sufficient to inhibit bacterial growth in vitro (Rukholm et al., 2006).   
The MIC of liposomal cyclo(Tyr-Pro) was determined using the broth dilution 
technique as described by the National Committee of Clinical Laboratory Standards 
(NCCLS).   
 
All pipette tips and equipment were sterilised by autoclaving at 121 ºC for 15 
minutes.  1000 ml of Mueller-Hinton broth (23 g dissolved in 1000 ml reverse 
osmosis water)  was made up as per manufacturer‘s instructions and autoclaved at 
121 º C for 15 minutes.  The Gram-positive bacteria S. aureus and B. cereus, Gram-
negative bacteria, E. coli and P. aeruginosa were selected as representative test 
organisms for this study. Fresh bacterial cultures were prepared as outlined in 
section 3.8, and the turbidity adjusted to 0.22 AU.  
 
Based on the encapsulation efficiency obtained for the different formulations, a 50 μL 
aliquot of liposomal cyclo(Tyr-Pro) for each of the bacteria was pipette into the top 
wells (A1 and 2) of a 96-well microplate.   The first two wells thus represented the 
highest drug concentration. The suspensions were then serially diluted in wells B to 
F.  Table 18 gives the dilutions of cyclo(Tyr-Pro) for the different bacteria. 
 
 
Table 18: Serial dilutions of cyclo(Tyr-Pro) in 96-well microplates for the different bacteria  
Organism Concentration of cyclo(Tyr-Pro) in well (mg/ml) 
Staphylococcus aureus 0.425 0.2215 0.10625 0.0531 0.0267 
Bacillus cereus 0.45 0.225 0.1125 0.0563 0.0281 
Escherichia coli 0.363 0.1815 0.09075 0.04534 0.0227 
Pseudomonas aeruginosa 0.412 0.206 0.103 0.0515 0.0258 
 
 
The rest of the wells (A3 to A8) contained free cyclo(Tyr-Pro) 20 mg/ml, the negative 
control solution and positive control solutions (1 mg/ml amoxicillin and 0.5 mg/ml 
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chloramphenicol) in saline with 5 % v/v DMSO.  These solutions were also serially 
diluted to give test concentrations of 10, 5, 2.5, 1.25 mg/ml; 0.5, 0.25, 0.125, 0.0625 
mg/ml and 0.25, 0.125, 0.0625, 0.03215 mg/ml of free cyclo(Tyr-Pro), amoxicillin and 
chloramphenicol respectively.    A 50 µl volume of the standardised bacteria was 
added to each well. The plates were then incubated at 37 ºC for 24 hours.  After 
incubation, 50 µl of MTT dye (0.5 mg/ml) was added to each well and further 
incubated for 60 minutes to allow for the metabolic reduction of MTT.  The plates 
were subsequently removed from the incubator and centrifuged at 3000 rpm for 7 
minutes to pellet the insoluble formazan precipitate (Freimoser et al., 1999).  The 
supernatant in each of the wells was aspirated and discarded.  The formazan 
product present was dissolved in 100 µl of DMSO.  The microplates were read at 
540 nm using a microplate reader.   The experiments were conducted in triplicate 
and a separate plate was used for each bacterium. 
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CHAPTER 4 
RESULTS AND DISCUSSION 
 
 
4.1 Particle size and zeta potential 
 
The results obtained are summarized in Table 19.  The analysis of the zeta potential, 
the electric potential at the plane of shear, is a useful method to predict the physical 
stability of nanoparticles during storage. 
 
Table 19: Measurements for particle size and zeta potential, values reported are the mean ± s.d. of 
triplicates  
Formulation Particle size (µm) Zeta potential (mV) 
1 4812 ± 66.16 -7.1 ± 1.975 
2 155.4 ± 2.42 - 24.1 ± 0.473 
3 165.2 ± 2.04 - 13.7 ± 1.40 
4 154.1 ± 2.68 - 15.3 ± 1.55 
5 245.6 ± 11.14 - 17.6 ± 1.789 
6 164.8 ± 4.99 - 14.6 ± 0.321 
7 149.7 ± 3.41 - 23.9 ± 2.15 
8 153.1 ± 0.78 - 11.5 ± 0.737 
9 169.5 ± 3.11 - 10.3 ± 0.873 
10 157.2 ± 1.73 - 16.8 ± 0.5 
11 155.6 ± 1.62 - 2.47 ± 0.918 
12 194.7 ± 13.97 - 13.4 ± 0.643 
13 176.7 ± 18.71 - 16.6 ± 2.928 
 
 
Because the size of formulation 1 was completely out of range with the other 
formulations, this formulation was left out of the study. The reason behind 
homogenization of liposome suspensions is to decrease liposome size, as well as to 
keep the size distribution at a minimum, thereby improving the macroscopic 
appearance of the suspension and also improving the physical stability of the system 
in terms of sedimentation or floating (Lasch et al., 2003).   
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Temperature and lipid composition are some of the variables that influence liposome 
size.  Because the liposome suspensions were filtered through a filter medium with a 
100 µm pore size, one would expect the size of the resultant liposomes to be smaller 
than or equal to this value.   
 
The mean particle size of the liposome vesicles ranged from 153 ± 0.78 to 245.6 ± 
11.14. This is because liposomes are extruded through these polycarbonate filters at 
temperatures higher than their transition temperatures, meaning, as they pass 
through the 100 µm pore, they are in a fluid state, are easy to deform and can easily 
regain their initial size after extrusion.  Another phenomenon which could explain the 
increase in liposome size post extrusion is secondary particle growth.  With certain 
mixtures of lipids, liposome sizes reach a minimum, followed by a re-increase in size 
with further extrusion cycles.  Ostwald ripening or fusion, which is a gradual increase 
in size of bigger particles at the expense of smaller ones by means of molecular 
diffusion, could be the reason behind secondary particle growth (Lasch et al., 2003).  
 
It is noteworthy that the biggest vesicle was obtained for the formulation which 
contained a higher proportion of DSPC to DMPC and cholesterol content.   
 
Zeta potential measurements of liposomes provide direct information on the structure 
of the lipid head group.  Phosphocholine, which is the most commonly used 
phospholipid to prepare liposomes is a neutral lipid, with one phosphatidyl group and 
one choline group in the molecule.  The neutral phospholipids composed of DMPC, 
DPPC and DSPC exhibit non-zero zeta potentials in an electric field, even when they 
are dispersed in a solution at pH 7.4.  In solutions of low ionic strength, the zeta 
potential is negative (Makino and Shibata, 2006).  From the zeta potential 
measurements in Table 19, the zeta potentials for all the formulations were negative.   
 
The significance of zeta potential is that its value can be related to the stability of 
colloidal dispersion. Zeta potential indicates the degree of repulsion between 
adjacent, similarly charged particles in a disperse system. For particles that are small 
enough, a high zeta potential will confer stability; dispersion will resist aggregation. 
When the potential is low, attraction exceeds repulsion and the dispersion will 
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flocculate. Therefore, disperse systems with high zeta potentials (negative or 
positive) are electrically stabilised while those with low zeta potentials tend to 
coagulate (Lasch et al., 2003; Attwood, 2007). It can be concluded that the various 
formulations were relatively stable.  Also, the issue of stability due to coagulation of 
colloidal particles becomes a problem with prolonged storage of liposome 
suspensions prior to use.  The formulations utilised in this study were produced and 
used within a reasonable period. 
 
4.2 Regression models of response 
 
The variables used for the factorial analysis were phospholipid composition (A) and 
cholesterol content (B).  The experimental responses for the 12 runs are represented 
in Table 20, and showed considerable variation in encapsulation and percent 
bacterial inhibition depending on the independent variables and their amounts in 
each formulation. 
 
 4.2.1 Encapsulation 
 
Encapsulation efficiency is defined as the ratio of the amount of active compound 
remaining in the liposome relative to the amount introduced.  It is influenced by a 
number of factors, namely, vesicle type, pH, method of preparation, liposome 
composition, the ratio of lipid to drug and the physicochemical properties of the 
liposome (Jia et al., 2008).  
  
Although the 12 liposome formulations were prepared in an identical way, their 
encapsulation efficiencies, differ significantly.  This was particularly important for the 
centre points which were identical in composition.  These discrepancies may be due 
to differences in rigidity and permeability of the membrane bilayer which is strongly 
dependent on the type and quality of (PC) and additional bilayer lipids used.  Alkyl 
chain length and degree of unsaturation play a major role, for example, an 18-carbon 
saturated alkyl chain produces rigid bilayers with a low permeability at body 
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temperature.  The presence of cholesterol also tends to rigidify bilayers (Storm and 
Crommelin, 1998).   
  
Table 20: Central composite design consisting of experiments for the study for two experimental   
factors in coded levels with experimental results 
Formulation A B Encapsulation (%) Bacterial inhibition (%) 
S.A
a 
B.C.
b 
P.A
c 
E.C 
d 
2 0 0 3.53 27.2 41.7 18.8 38.08 
3 0 0 3.78 13.6 30.8 16.0 41.1 
4 +1.414 0 5.36 48 56.8 58 57.7 
5 -1 +1 5.01 44 49.4 56.9 52.4 
6 -1 -1 4.12 38 53.2 44.3 53.06 
7 0 +1.414 3.61 48 52.7 44.7 54.7 
8 0 0 2.95 25.6 36 37.8 33.8 
9 0 0 4.22 23.6 29.1 36.3 30 
10 -1.414 0 2.61 19.6 20.2 46.2 55.4 
11 0 0 3.26 32 43 32.1 44.4 
12 0 -1.414 4.46 36.8 40.9 33.5 56 
13 +1 +1 3.23 32.4 38 42.4 41.4 
a: S.A. – Staphylococcus aureus; b: B.C – Bacillus cereus; c: P.A – Pseudomonas aeruginosa; d: E.C 
– Escherichia coli 
 
In this study, phospholipids with 16 and 18 alkyl carbon chains as well as cholesterol 
were used.  From Table 20, the highest percent encapsulation was obtained for the 
formulation which contained a higher proportion of DMPC, a 16-carbon lipid, while 
the lowest was observed to be the formulation with a higher proportion of DSPC, an 
18-carbon phospholipid.  There were significant differences in the encapsulation 
efficiencies of the centre points, which indicated significant error in the model.   
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4.2.2 Susceptibility patterns of experimental bacteria to the different liposomal 
formulations 
 
The antibacterial activity of the various liposomal cyclo(Tyr-Pro) formulations against 
S. aureus, B. cereus, E. coli and P. aeruginosa are represented in Table 20.  The 
most efficient of the tested lipid formulations were liposomes composed of 
DMPC/DSPC/Chol 92.4:7.6:30.  There were significant differences in the activities of 
the liposomal formulations against the various bacteria.  This can be ascribed to the 
differences in structure and composition of the various bacteria, which may have 
resulted in dissimilar uptake rates of the different formulations (Lambert, 2002). 
 
4.2.3 Selection of optimum parameters 
 
The computer software, Design Expert 8 was used for the experimental design and 
regression analysis of the experimental data obtained.  The analysis of variance 
(ANOVA) for the response surface quadratic model is shown in Tables 21 and 22.  
The quality of fit of the model equation was expressed by the co-efficient of 
determination R2 which provides a measure of the proportion of variation (through a 
regression equation), for instance, an R2 value of 0.999 indicates that 99.9 % of the 
response variability can be explained by the model.  Normally, a regression model 
having an R2 value higher than 0.9 is considered to have a high correlation (Li et al., 
2007). The closer the value of R (correlation coefficient) to 1, the better the 
correlation between the experimental results and the predicted value.   
 
Table 21: Analysis of variance table – Response 1: Percent bacterial inhibition 
Source B. cereus S. aureus E. coli P. aeruginosa 
Model p-value 0.1406 0.2031 0.0462 0.1012 
AB p-value 0.1563 0.3507 0.2333 0.4090 
Lack of fit 0.0060 0.1392 0.3905 0.6616 
R2 0.680 0.6313 0.791 0.7201 
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Table 22: Analysis of variance table – Response 2: Encapsulation 
Source of variance p-value R2 
Regression 0.3465 0.5366 
Lack of fit 0.0772 - 
AB 0.0983 - 
 
 
Only significant terms were chosen for the final equations. In order to optimise the 
encapsulation efficiency and percent bacterial inhibition, the following mathematical 
equations were derived using Design Expert 8.0: 
 
For response 1:  Percent bacterial inhibition: 
 
YB.C = 24.24 + 5.59A – 4.37B – 6.49AB + 4.49A
2 + 7.39B2  (1)   
  
YS.A = 24.40 + 5.08A + 0.52B – 5.93AB + 5.46A
2 + 9.76B2  (2) 
 
YE.C. = 37.48 + 0.18A – 2.92B – 5.05AB + 8.62A
2 + 8.02B2  (3) 
 
YP.A = 28.40 + 1.15A + 2.51B – 5.24AB + 12.63A
2 + 6.13B2  (4) 
 
For response 2:  Encapsulation: 
 
Y = 3.55 + 0.54A – 0.40B – 0.95AB + 0.38A2 + 0.41B2   (5) 
 
These equations are second order response functions representing percent 
encapsulation and percent bacterial inhibition expressed as functions of the two 
independent variables (cholesterol content and phospholipid composition).  The 
predicted values for both percent encapsulation and percent bacterial inhibition with 
the experimental values are given in Table 23.  The predicted and experimental 
models are represented in Figures 24 - 28.   
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Table 23: Experimental and predicted values for bacterial inhibition and percent encapsulation 
Organism Phospholipid Cholesterol  Inhibition (%) Encapsulation 
(%) 
(%) (%) Predicted Actual Predicted Actual  
S. aureus 15 50 79.8 80.12 6.5 4.25 
B. cereus 87.26 15.61 71.3 91.5 7.94 4.5 
E. coli 70 10.86 82.86 73.68 7.56 3.63 
P. aeruginosa 97.5 13.75 87.49 82.20 9.5 4.12 
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Figure 24: Relationship between the predicted and experimental encapsulation values.  
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Figure 25: Relationship between the predicted and experimental values for percent bacterial inhibition 
for Bacillus cereus 
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Figure 26: Relationship between the predicted and experimental values for percent bacterial inhibition 
for Staphylococcus aureus 
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Figure 27: Relationship between the predicted and experimental values for percent bacterial inhibition 
for Escherichia coli 
 
Design-Expert® Software
Percent inhibition
Color points by value of
Percent inhibition:
58
16
X: Actual
Y: Predicted
Predicted vs. Actual
10.00
20.00
30.00
40.00
50.00
60.00
10.00 20.00 30.00 40.00 50.00 60.00
 
Figure 28: Relationship between the predicted and experimental values for percent bacterial inhibition 
for Pseudomonas aeruginosa 
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Reliability and adequacy of the empirical models from the respective responses was 
confirmed when the actual values obtained from the experiments were compared to 
the estimated values from the regression models.  Points above the diagonal line 
were those that were over-estimated and vice-versa.  All five graphs represented in 
Figures 24 – 28 indicated that the experimental design points were not distributed 
along the diagonal line.  Experimental results were thus not well-fitted when 
compared to the predicted values from the empiric model.  The values of R2 
indicated the lack of agreement between the experimental results and the theoretical 
values predicted by the model equations.  This lack of agreement was also evident in 
Table 23, which clearly showed the differences in the predicted and experimental 
results.   
 
RSM has the advantage of observing interaction effects among independent 
variables.  Interaction occurs when one factor does not produce the same effect on a 
response at different levels of another factor.  If the lines are parallel, there is no 
interaction. On the contrary, when the lines cross, the factors are interacting 
(Bradley, 2007). Interaction plots for both encapsulation and bacterial inhibition are 
plotted graphically in Figures 29 – 33 based on the mathematical analysis of the 
experimental data.    
 
P-values are also given in Tables 21 and 22.  These values were used as a tool to 
check the significance of the coefficients in equations 1 – 5, which in turn were 
necessary to understand the pattern of mutual interactions between the variables.  
The smaller the p-values were, the bigger the significance of the corresponding 
coefficient (Li et al., 2007).  From the model p-values, it was evident that the models 
were highly insignificant.  The model for E. coli was more significant, with a model p-
value of 0.0462 (P < 5 %), lack-of-fit value which was not significant at 0.3905 (P > 5 
%) and R2 value of 0.7914, when compared to the other models.    
 
It was obvious that there were major interactions between the two independent 
variables (AB) and responses one and two.  The non-parallel curves  imply that there 
was a strong interaction between cholesterol content and phospholipid composition.  
As a result of this strong interaction, the AB term appeared as one of the significant 
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terms in equations 1 – 5.  The p-values were also an indication of the interaction 
between the two terms.  It was thus concluded that the two factors did not have a 
linear effect on the responses because the observed response did not necessarily 
increase with increasing levels of each factor.   
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Figure 29: Graphical representation of the effect of phospholipid composition and cholesterol content 
on encapsulation 
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Figure 30: Graphical representation of the effect of phospholipid composition and cholesterol content 
on the inhibition of Bacillus cereus growth 
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Figure 31: Graphical representation of the effect of phospholipid composition and cholesterol content 
on the inhibition of Escherichia coli growth 
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Figure 32: Graphical representation of the effect of phospholipid composition and cholesterol content 
on the inhibition of Pseudomonas aeruginosa growth 
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Figure 33: Graphical representation of the effect of phospholipid composition and cholesterol content 
on the inhibition of Staphylococcus aureus growth 
 
In order to gain a better understanding of the two variables for optimum liposome 
performance, the models were represented as 3-D surface graphs, and these are 
represented in Figures 34 - 38. 
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Figure 34: Response surface plot of the combined effects of phospholipid and cholesterol content on 
encapsulation 
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Figure 35: Response surface plot of the combined effects of phospholipid and cholesterol content on 
the inhibition of Bacillus cereus 
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Figure 36: Response surface plot of the combined effects of phospholipid and cholesterol content on 
the inhibition of Escherichia coli 
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Figure 37: Response surface plot of the combined effects of phospholipid and cholesterol content  on 
the inhibition of Pseudomonas aeruginosa 
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Figure 38: Response surface plot of the combined effects of phospholipid and cholesterol content on 
the inhibition of Staphylococcus aureus 
 
Figure 34 illustrates the effects of phospholipid composition and cholesterol content 
on the encapsulation of cyclo(Tyr-Pro).  It was observed that high initial cholesterol 
content with a lower proportion of DMPC relative to DSPC in the formulation resulted 
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in a high encapsulation efficiency.  It was found that increasing the DMPC 
component had a negative effect on the encapsulation efficiency, evident in the dip 
of the graph with increasing DMPC concentration.  The highest encapsulation 
efficiency however was achieved with a formulation with low cholesterol content and 
a higher proportion of DMPC relative to DSPC.     
A similar trend was observed in Figures 35 - 38 where percent bacterial inhibition 
was higher initially, when the lipid composition contained more DSPC relative to 
DMPC, and high cholesterol content.  The highest percent inhibition was 
accomplished where the lipid component contained a higher molar ratio of DMPC 
than DSPC with low cholesterol content.  
It was observed that the biological activity of liposomes containing a higher molar 
ratio of the low Tc phospholipid (DMPC) and a lower cholesterol content (less than 
20 %) exhibited better biological activity than those with a lower proportion of the 16-
carbon lipid (more DSPC) and a higher cholesterol content (more than 40 %).  
Physicochemical properties such as membrane fluidity and permeability determine 
liposomal biological activity. Liposomes exhibit various phase transitions that might 
be used to trigger drug release or liposome fusion upon an appropriate trigger (Lasic, 
1998).  The presence of high Tc lipids makes the membrane bilayer more rigid at 
body temperature and less leaky.  In contrast, liposomes made up of low Tc lipids 
are more susceptible to leakage of drugs encapsulated into the mobile phase at 
physiological temperatures.  The presence of cholesterol tends to rigify liposomes, 
further decreasing their permeability (Sharma and Sharma, 1997; Storm and 
Crommelin, 1998; Banerjee, 2001).    
Lipid bilayers can exist in a low-temperature solid–ordered phase and, above a 
certain temperature, in a fluid–disordered phase; the temperature of this phase 
transition, Tc, can be tailored by selecting the proper lipids.   It was thus concluded 
that a formulation containing a higher proportion of DMPC to DSPC with low 
cholesterol content was ideal for optimal activity. 
 
The model selected by Design Expert 8 as best-fitting for the experimental data was 
the quadratic model.  The coefficient of determination, R2 is an indication of how 
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closely the model fits the experimental data.  The R2 values obtained in this study 
demonstrated that the fitting of the experimental data to the quadratic model was not 
optimal.  P-values were also included and they were used as a tool to check the 
significance of the coefficients in equations 1 – 5, which are second order response 
functions representing percent encapsulation and percent bacterial inhibition 
expressed as functions of the two independent variables, which in turn were 
necessary to understand the pattern of mutual interactions between the variables.   
When selecting a second-order response surface design for response optimisation, 
we want to select a design that will provide a good-fitting model to the data, and, in 
particular, provide reliable parameter estimates, which then can be used for precise 
predictions (Myers et al., 2009).  
   
There were significant inconsistencies in the experimental results obtained for the 
centre points of this design, which led to failure of the predicted model to fit the 
experimental results.  This was evident in the p-values and lack-of-fit values.  The 
omission of run 1, a factorial point, from the experiment may have also contributed to 
the lack-of-fit of the experimental data to the quadratic model.   A common problem 
encountered in the manufacture or production of liposomes is maintaining batch-to-
batch reproducibility (Sharma and Sharma, 1997; Storm and Crommelin, 1998).  
This problem may have resulted in the discrepancies observed in the centre point 
replicates.  
A logical approach to this short-coming would have been to add more replicates at 
the centre in an attempt to reduce the total error, or alternatively to add more axial 
points, as the outcome of the model would be improved with the addition of more 
runs.  However, due to time and financial constraints, any attempt at these potential 
solutions was not possible. 
Although the activity of the various liposome formulations was affected by changing 
the lipid composition of these vesicles, method of preparation, the technique used in 
the quantification of encapsulation, as well as differences in bacterial structure also 
had an effect on their activity.  This was evident in the significant differences in 
activities of the various formulations against the four bacteria.  It is well documented 
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that thin-film hydration, the method used for liposome production in this study, 
although simple, leads to poor encapsulation efficiencies (Sharma and Sharma, 
1997).  Centrifugation was the technique of choice for separating free drug from 
encapsulated drug prior to quantifying encapsulation efficiency.  This method 
requires centrifugation of liposome suspensions at high speeds for prolonged 
periods of time, depending on the speed of the motor being used, which could have 
potentially caused leakage of liposome contents, thereby decreasing total 
encapsulated drug.    
Differences in biological activity of the different formulations necessitated that a 
unique formulation be optimized for each bacterium.  Although necessary for optimal 
activity against different bacteria, optimizing exclusive formulations for each 
pathogen would be impractical in a clinical setting.  This would effectively mean that 
each strain of a particular organism would require a unique formulation for optimal 
antibacterial activity. 
 
4.3 Determination of minimum inhibitory concentration 
 
MIC is defined as the minimum concentration of an antibiotic that is sufficient to 
inhibit bacterial growth in vivo (Rukholm et al., 2006).  Evaluation of microbial growth 
becomes important when looking into the antimicrobial effects of a compound. At the 
concentrations of cyclo(Tyr-Pro) tested, it was not possible to quantify the MIC of the 
different formulations against the various bacteria.   
 
The effects of the positive controls, (amoxicillin for Gram-positive organisms and 
chloramphenicol for Gram-negative organisms), liposomal cyclo(Tyr-Pro) and free 
cyclo(Tyr-Pro) on the survival rates of two Gram-positive bacteria namely Bacillus 
cereus and Staphylococcus aureus, and two Gram-negative bacteria namely, 
Escherichia coli and Pseudomonas aeruginosa were compared using dose-response 
curves. 
A dose-response curve describes the relationship between response to a drug and 
the drug dose or concentration.  The term "dose" strictly only applies to experiments 
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performed with animals or people, where various drug doses are administered and 
the actual drug concentration is not known. However, the term "dose-response 
curve" is also used more loosely to describe in vitro experiments where known 
concentrations of drugs are applied.  Response is directly proportional to receptor 
binding and binding maximum or Bmax, is achieved when all the receptor sites are 
occupied (Motulsky, 2003; Wilson, 2010).   , 
A standard dose-response curve is defined by four parameters: the baseline 
response, maximal response or Bmax, the slope of the curve and the drug 
concentration halfway between the baseline and the maximal response, the IC50. 
IC50 is the concentration of an inhibitor where the response is reduced by half. 
 The general equation for a variable slope sigmoidal dose-response curve is: 
Y = Bottom + (Top – Bottom)/ 1 + 10 (log IC50
 – X) * Hillslope 
  
X = the logarithm of concentration, Y = response, log IC50 is the logarithm of IC50 and 
hillslope is the steepness of the curve.  A standard curve has a hillslope of 1.0.  
When the hillslope is less than 1.0, the curve is more shallow and said to be steeper 
when this value is more than 1.0 (Harvey and Christopolous, 2003).   
Because drug effect is a function of dose and time, such a graph represents the 
dose-response relationship independent of time.  An agonist is a compound that is 
able to elicit a maximal response following receptor occupation and activation.  If 
various concentrations of an agonist are administered, the dose-response curve will 
go uphill as you go from left (low concentration) to right (high concentration).  A 
partial agonist is a drug that provokes a response, but the maximum response is less 
than the maximum response to a full agonist (Motulsky, 2003).   
Since the linkage between agonist binding and response can be very complex, any 
shape is possible, but typically, dose response curves have a sigmoidal shape. The 
amount drug is plotted as the log of drug concentration, giving dose-response curves 
their characteristic sigmoidal shape (Motulsky, 2003).   
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The mathematical programme GraphPad Prism version 4 (San Diego, California, 
USA) was used to analyse the effects of increasing drug concentration and also to 
compare the effects of the different compounds on bacterial growth.   Figures 39 - 42 
represent dose-response curves and results for each bacterium.  Curve fitting finds 
the curve that minimises the sum-of-squares of the vertical distance from the points 
(Motulsky, 2003).    
-0.75 -0.50 -0.25 0.00 0.25 0.50 0.75 1.00 1.25 1.50
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
Liposomal cyclo(Tyr-Pro)
Free cyclo(Tyr-Pro)
Log concentration (mg/ml)
B
a
c
te
ri
a
l 
in
h
ib
it
io
n
 (
%
)
 
Figure 39: Dose response curve representing percentage inhibition of B. cereus after 24 hours 
exposure to liposomal cyclo(Tyr-Pro) and free cyclo(Tyr-Pro)  
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Figure 40: Dose response curve representing percentage inhibition of E. coli after 24 hours exposure 
to liposomal cyclo(Tyr-Pro) and free cyclo(Tyr-Pro) 
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Figure 41: Dose response curve representing percentage inhibition of P. aeruginosa after 24 hours 
exposure to liposomal cyclo(Tyr-Pro) and free cyclo(Tyr-Pro) 
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Figure 42: Dose response curve representing percentage inhibition of S. aureus after 24 hours 
exposure to liposomal cyclo(Tyr-Pro) and free cyclo(Tyr-Pro) 
 
A dose-response curve has features that vary: Potency refers to the location of the 
curve along the x-axis; maximal efficacy or ceiling effect is the greatest attainable 
effect and lastly the slope, which indicates the change in response per unit dose.   
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In Figure 39, the effects of liposomal and free cyclo(Tyr-Pro) against the Gram-
positive Bacillus cereus are illustrated.  The R2 values are 0.9871 and 0.8366 for the 
encapsulated and free compound respectively.  It was evident from the graph, as 
well as the R2 value that the data of the latter graph did not fit the model well.    
 
Significant inhibition of B. cereus growth by liposome-encapsulated cyclo(Tyr-Pro) 
occurred at concentrations as low as 0.450 mg/ml. The binding maximum or Bmax for 
liposomal cyclo(Tyr-Pro) at this concentration was 91.25 %, compared with 50 % 
obtained for the free compound at a concentration of 20 mg/ml.  At full receptor 
occupancy and at a concentration more than 20-fold that of the encapsulated CDP, 
free cyclo(Tyr-Pro) failed to elicit a maximal response. Free cyclo(Ty-Pro) can thus 
be regarded as a partial agonist as the maximum response provoked was 
remarkably less than that observed for the encapsulated CDP. The antibacterial 
activity of liposome encapsulated cyclo(Tyr-Pro) was clearly superior to that of non-
entrapped CDP.  This was evident in the IC50 value of 1.930 for the encapsulated 
drug, which was twice that of the free compound (4.134).   
 
Figure 40 illustrates the effects of liposome encapsulated cyclo(Tyr-Pro) and its non-
encapsulated counterpart against Escherichia coli.  The experimental data for E. coli 
did not fit the graph model.  The one graph was in the exponential phase (liposomal 
cyclo(Tyr-Pro), while the other was in the plateau phase.  The R2 values for the two 
graphs were 0.9553 for the encapsulated CDP and 0.6152 for the free CDP.  The 
significant lack-of-fit of these graphs made it impossible to properly analyse the 
graphs.   
 
Figures 41 and 42 illustrate the effects of liposomal cyclo(Tyr-Pro) and its free 
counterpart against S. aureus and P. aeruginosa.  R2 values for Figure 41 were 
0.9907 and 0.8918 for encapsulated and free cyclo(Tyr-Pro) respectively, which 
indicated a better fit for the former graph.  Bmax for the liposomal compound was 82.9 
at a concentration of 0.412 mg/ml and that of its free counterpart was 45 % at 20 
mg/ml.  The IC50 values were 1.391 and 3.466 for the encapsulated and free 
cyclo(Tyr-Pro) respectively.  Encapsulation of cyclo(Tyr-Pro) into a liposome 
formulation therefore enhanced its antibacterial activity. 
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A similar trend was observed with S. aureus inhibition.  R2 values for Figure 42 were 
0.9730 for the encapsulated CDP and 0.9240 for its free counterpart. The lack-of-fit 
was not extensive.  The antibacterial activity cyclo(Tyr-Pro) was remarkably 
enhanced by encapsulation of this compound into a liposome formulation.  Bmax for 
liposomal cyclo(Tyr-Pro) was 78.5 % at a concentration of 0.425 mg/ml and that of 
its free counterpart was 47.6 % at 20 mg/ml. The IC50 for the liposomal cyclo(Tyr-
Pro) was 1.043 and 1.821 for the free CDP which was remarkable because the 
concentration of the free CDP was more than 20-fold that of its encapsulated 
counterpart.  
 
Liposome preparations of some drugs have shown a significant increase in the 
efficacy or therapeutic indices in pre-clinical models and humans compared to their 
―free‖ counterparts (Omri et al., 2002; Mugabe et al., 2006).  Entrapment of 
antimicrobial agents into liposomes has been shown to enhance their therapeutic 
effectiveness (Beaulac et al., 1996; Omri and Ravaoarinoro, 1996; McAllister et al., 
1999).   This is because liposomes can interact with target cells in various ways and 
are therefore able to promote intracellular delivery of drugs that in their free form 
would not be able to enter the cell due to unfavourable physicochemical 
characteristics. Furthermore, liposome-encapsulation of these agents protects them 
from extracellular degradation and promotes their delivery to the desired site of 
action, meaning that lower doses of the desired drug can be administered 
(Momekova et al., 2007).   
 
Not only was liposome-encapsulated cyclo(Tyr-Pro) more effective in inhibiting 
bacterial growth, it was also more potent than free cyclo(Tyr-Pro), because lower 
concentrations of the liposomal CDP were required to elicit responses that free 
cyclo(Tyr-Pro) at a concentration of 20 mg/ml could not elicit.   These findings are 
remarkable because the concentration of free cyclo(Tyr-Pro) tested against the 
different bacteria was more than 20-fold that of the liposomal formulations.  The 
activity of liposomal cyclo(Tyr-Pro) was clearly better against the Gram-positive 
organisms, particularly B. cereus. 
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CHAPTER 5 
CONCLUSION AND RECOMMENDATIONS FOR FURTHER RESEARCH 
 
5.1 Conclusion 
Cyclo(Tyr-Pro) is an amino acid-based cyclic dipeptide that was shown by Graz 
(2002) to possess antibacterial activity, particularly against Gram-positive bacteria.  
Entrapment of certain compounds into liposome formulations has been shown to 
enhance their effectiveness by protecting them from enzymatic degradation, 
promoting their intracellular delivery and lastly by modifying their intracellular 
distribution.    
This study aimed to optimize a liposomal formulation containing cyclo(Tyr-Pro) using 
RSM and CCD, and to test its antibacterial activity against Bacillus cereus, 
Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. This was 
achieved through encapsulating cyclo(Tyr-Pro) into liposome formulations, 
characterising these formulations in terms of encapsulation efficiency and testing 
their antibacterial activity against the four bacteria.  The MTT assay was used to 
determine the antibacterial effects of liposomal cyclo(Tyr-Pro) in comparison to that 
of its free counterpart.  Amoxicillin was used as a positive control for the Gram-
positive bacteria and chloramphenicol served as a positive control for the Gram-
negative organisms.    
The mathematical software, Design Expert 8 was used for the purpose of finding the 
combination of process variables (cholesterol and phospholipid content) that would 
yield optimal formulations for each bacterium.  The model selected by the software 
failed to adequately correlate the predicted models to the experimental data.  This 
was attributed to the discrepancies in batch-to-batch reproducibility encountered in 
the production of liposomes. 
On the other hand, the results of this study indicated, clearly, that encapsulating 
cyclo(Tyr-Pro) into liposome formulations enhanced the antibacterial activity of this 
compound.  This was evident in the superior activity of this peptide against the 
bacteria tested at concentrations more than twenty-fold less than its non-
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encapsulated counterpart, especially against Gram-positive organisms.  These 
results are remarkable, considering the widespread resistance problem where most 
health professionals would prefer a novel chemical class with no pre-existing 
potential cross-resistance.  Despite several decades of improved therapy and 
prevention of infectious diseases, infectious pathogens remain the major cause of 
morbidity and mortality in humans worldwide.  Antibiotic resistance in bacterial 
pathogens continues to evolve and spread globally, posing a grave threat to society 
(Pavia, 1999).  Unfortunately, relatively few new antimicrobial agents have been 
developed in recent years. 
As pharmaceutical development has moved toward rational drug design, where 
therapies are engineered to interfere with or block disease mechanism, peptides are 
gaining more and more importance as versatile intermediates and active materials 
(Bernagen, 1995). The importance of peptides as central modulators of many 
biological functions has become increasingly evident and this has lent them the 
potential to be among the major candidates in the search for new drugs (Haywood, 
2000). 
Liposomes have matured as a delivery system for therapeutic agents.  It has taken 
over 3 decades to develop the liposome carrier concept to a pharmaceutical product 
level.  Areas of application are wide, and include the treatment of major diseases 
including severe infections, cancer and metabolic disorders.   
In conclusion, the data included in this study suggests that the incorporation of 
cyclo(Tyr-Pro) into liposome formulations enhanced its in vitro activity against the 
bacteria studied. 
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5.2 Recommendations for further research 
It was concluded that explaining the effect of phosholipid and cholesterol content on 
the in vivo and in vitro behaviour of liposomes using a second order polynomial was 
not possible.  To overcome this, it is recommended that the data be converted to 
another form than can be explained by the second order model.   Alternatively, to 
add more replicates at the centre in an attempt to reduce the total error, or 
alternatively to add more axial points, as the outcome of the model would be 
improved with the addition of more runs.  
 
Another recommendation is that the exact site of antibacterial action of cyclo(Tyr-
Pro) be elucidated in order to rationally enhance the antibacterial efficacy of CDPs.   
Also, some work needs to be done to determine the effect of bacterial structure on 
bacterial liposome uptake, in the aim to optimise a single liposomal formulation with 
a broad spectrum of antibacterial activity. 
 
Some of the problems that were encountered in this study in terms of liposome 
production were low entrapment efficiencies, maintaining batch-to-batch 
reproducibility and particle size control.  Further studies could look at improving 
encapsulation by using active or remote loading strategies that have been 
developed, increasing encapsulation efficiencies up to 96 % (Stensrud et al., 2000).  
Alternatively, the use of the freeze-dried liposome rehydration method, which often 
offers higher encapsulation efficiency than the thin lipid-film method could be 
investigated.   
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Abstract 
Response surface methodology (RSM) using the central composite rotatable design 
(CCRD) was used to optimise a liposomal formulation of cyclo(Tyr-Pro).  A CCRD 
consisting of a two-factored factorial design with five levels was used in this study.  
Drug encapsulation efficiency and percent bacterial inhibition were investigated with 
respect to two independent variables: phospholipid composition and cholesterol 
content.  The results showed that an optimal formulation containing 50 % cholesterol 
and a 15 % lipid composition could be obtained from the design model, which, under 
the optimised conditions would give rise to an encapsulation of 6.5 % and a 71.9 % 
bacterial inhibition. The experimental data obtained did not match the data predicted 
by the model. 
The in vitro experiments proved that the antibacterial activity of liposome-
encapsulated cyclo(Tyr-Pro) against Staphylococcus aureus was superior to that of 
its free counterpart.  Bmax for the encapsulated compound at a concentration of 0.425 
mg/ml was 78.5 % compared to 47.6 % obtained for the free compound at a 
concentration of 20 mg/ml.  IC50 values were 1.043 and 1.821 for the encapsulated 
cyclic dipeptide and its free counterpart respectively. 
Key words: Response surface methodology, central composite design, cyclo(Tyr-
Pro), liposome  
 
 
 
 
 
1.1 Introduction 
Problems associated with increasing antibiotic resistance and decreased 
development of antibacterial agents with novel mechanisms of action has 
necessitated extensive research into antimicrobial peptides as a foundation on which 
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to target microorganism death by mechanisms that do not aid in the development of 
resistant strains (McInnes et al., 2000; Roberts et al., 2008).  Cyclic dipeptides 
(CDPs) are amino-acid-based compounds some of which possess antimicrobial 
activity (Prasad, 1995).  Although the existence of CDPs has been known since the 
beginning of the century, they have only recently drawn a considerable amount of 
interest (Graz et al., 1999).  This is possibly because a large number of naturally 
occurring CDPs have more recently been shown to possess powerful and useful 
biological effects.  Cyclic dipeptides have been synthesised, and studied, both 
structurally and functionally in the Cyclic Peptide Research Unit at the Nelson 
Mandela Metropolitan University since 1998 (Milne et al., 1998; Graz, 2002).  The 
wide spectrum of their biological properties points to various therapeutic possibilities.  
These peptide-based agents have been shown to exhibit potential as antibiotics, 
muscle relaxants and anticancer compounds, as well as in the treatment of 
cardiovascular dysfunction (Milne et al., 1998; Graz et al., 1999; Haywood, 2000).   
Selected CDPs previously tested showed marked antibacterial activity (Milne et al., 
1998; Graz, 2002). A study conducted by Graz (2002) investigated the antibacterial 
effects of 24 CDPs.  Their activity was measured against various Gram-negative and 
Gram-positive bacteria, by means of the Kirby-Bauer Assay.  The results indicated 
that proline-containing CDPs were the most effective in terms of antibacterial activity. 
Unfortunately, the potential of peptides for development as therapeutic agents for 
clinical use is hindered by various obstacles to their successful delivery (Tan et al., 
2010).  Functional properties such as side chains, as well as terminal amino and 
carboxy groups can drastically limit the peptide‘s ability to permeate biological 
barriers and also restrict its access to the target site (Lambert et al., 2001).  For this 
reason, a carrier or delivery system for therapeutic proteins and peptides would be 
ideal. 
The encapsulation of certain drugs into liposomes has been found to improve their 
activity in terms of bioavailability and duration of action. First designed in the 1960s, 
liposomes are spherical lipid bilayers ranging from 50 nm to 1000 nm in diameter.  
Liposomes serve as convenient delivery vehicles for biologically active compounds 
for the following reasons:  They can be used to provide targeted (cellular or tissue) 
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delivery of drugs; they help improve bioavailability of encapsulated drugs; they 
provide sustained release and can also be used to solubilise drugs for systemic use. 
They contribute to increasing efficacy and minimising toxicity of encapsulated 
compounds (Alipour et al., 2008; Singh and Lillard, 2009).  Because liposome 
formulations differ in physicochemical properties due to membrane fluidity (which is a 
function of the constituent lipids and their molar ratios in the formulation), surface 
charge, as well as size, they can be optimised in terms of drug content (percent 
encapsulation) and cellular uptake or biological activity by modifying these 
parameters (Sharma and Sharma, 1997).  
 
 
1.2  Response surface methodology 
 
One of the methodologies employed when optimising experiments is response 
surface methodology (RSM).  RSM is a collection of statistical and mathematical 
techniques useful for developing, improving and optimising processes in which a 
response of interest is influenced by several variables and the objective is to 
optimise this response (Myers et al., 2009).  The present study thus aimed to 
optimise a liposomal formulation of cyclo(Tyr-Pro) using statistical methods and to 
test its antibacterial activity against Staphylococcus aureus. 
 
 
1.3 Experimental design 
 
The response surface is drawn by predicting the mean outcome as a function of 
inputs over the region of experimentation.  A central composite rotatable design 
(CCRD) was chosen as the experimental design for finding out the exact quantitative 
relationship between the response (percent bacterial inhibition and percent 
encapsulation) and the input variables.   
The number of runs required for a CCRD include the standard 2k factorial with its 
origin at the centre, 2k points fixed axially at a distance, say α, from the centre to 
generate the quadratic terms and replicate tests at the centre, where k is the number 
of variables.  The experimental region extended from – 1.414 to 1.414 in terms of 
coded levels of independent variables, and α was chosen as 1.414.  To maintain 
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rotatability, the value of α depends on the number of experimental runs in the 
factorial portion of the CCD: α = [number of factorial runs]1/4 (Hendricks et al., 1996). 
In order to obtain the required data, the ranges of values for the two variables were 
defined as follows: Cholesterol content of 16 – 44 % and a phospholipid composition 
of 7.6 – 92 %.  The actual levels were calculated as follows: 
Actual level = Coded level * (high level – low level)/2 + (high level + low level)/2   
A two factorial design with a total of 13 runs augmented by four factorial points, four 
axial points and five replicates at the centre point was conducted.  Replicates of the 
test at the centre were included to provide an independent estimate of the 
experimental error.  The two factors that were varied are cholesterol content and 
phospholipid concentration. 
 
2 Materials and methods 
 
2.1 Materials 
1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC) and 1,2-Distearoyl-sn-
Glycero-3- Phosphatidylcholine (DSPC)  were purchased from Avanti Polar Lipids 
(Alabaster, AL, USA) while cholesterol was purchased from Northern Lipids 
(Barnaby, BC, Canada). Amoxicillin, chloramphenicol, Mueller-Hinton broth and MTT 
or [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide] were purchased 
from Sigma-Aldrich (St Louis, MO, USA). Cyclo(Tyr-Pro) was purchased from 
Bachem (Bubendorf, Switzerland). HPLC solutions were purchased from Merck 
(Darmstadt, Germany).  Staphylococcus aureus was an ATCC strain obtained from 
the Department of Biomedical Technology at the Nelson Mandela Metropolitan 
University.  All other chemicals and reagents were obtained from local suppliers and 
were of analytical grade. 
2.2 Preparation of liposome encapsulated cyclo(Tyr-Pro) 
Lipid compositions of the various liposomes used in the experiment are provided in 
Table 1.  Appropriate amounts of the lipids (DMPC, DSPC and cholesterol) were 
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dissolved in 5 ml of a 4:1 mixture of cholesterol and methanol in a 50 ml round-
bottom flask (60 mg total lipid). The percentage of A as seen in Table 1 represents 
the molar portion of DMPC in the formulation and the remainder (100 – DMPC) is 
that of DSPC, and B represents the molar amount of cholesterol.  In brief, the 
organic solution used to dissolve the lipids was removed under vacuum at 60 ºC, 
using a rotary evaporator (Buchi B495, Flawil, Switzerland).  To the dry lipid film, 5 
ml of an aqueous solution of cyclo(Tyr-Pro) at a concentration of 10 mg/ml was 
added.  DMSO was also added to this solution such that the final concentration was 
5 % v/v.  The resultant suspension was shaken on a shaking water bath at 60 ºC for 
3 hours to allow hydration of the lipid film, and then subsequently extruded 15 times 
through a 100 µm pore size Whatman Cyclopore Track etched membrane using a 
mini extruder (Avanti Polar Lipids, Alabaster).     
Unencapsulated cyclo(Tyr-Pro) was removed by ultra-centrifugation at 13 500 rpm 
(Lasec Hermle 2300, Wehingen, Germany) for 3 hours, and the pellet re-suspended 
in PBS (pH 7.4). The quantification of cyclo(Tyr-Pro) in liposomes was performed by 
the HPLC method. Liposome lysis was achieved by adding 100 µl of a 10 % Triton-X 
100 solution to 100 µl of liposome suspension in a centrifuge tube with subsequent 
incubation at 60 ºC for 1 hour to facilitate membrane breakdown.  The resultant 
solution was made up to 1000 µl with PBS and subsequently filtered through 0.45 
µm 0.45 µm PVDF membrane filter (Millex ® Syringe Driven Filter Units, Millipore 
Corporation, Bedford) prior to HPLC analysis. The chromatographic system 
consisted of the Shimadzu® LC2020 System (Kyoto, Japan), SPD M20A Photodiode 
Array (PDA) detector; S/L 20A autosampler; DGU 20A5 degasser; CTO 10AS VP 
column oven and a LC 20AB liquid chromatogram.  The HPLC apparatus was fitted 
with a Phenomenex® Luna C8 HPLC 5μm spherical column, with dimensions 15 cm 
x 4.6 mm and the oven temperature was set at 40 ºC.  The chromatographic mobile 
phase consisted of 12 % v/v HPLC grade acetonitrile and 88 % v/v reverse osmosis 
water.  10 µl samples were injected onto the HPLC column and run at a flow rate of 
1.0 ml/min.  The PDA detector was read at a wavelength of 220 nm.   
The results were calculated based on a standard curve prepared for cyclo(Tyr-Pro), 
concentration range of 0.597 – 0.0373 mg/ml. 
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Liposome size and zeta potential were routinely determined on a Zetasizer ZS 
(Malvern Instruments Ltd., Malvern, UK). Lipid concentration was determined 
colorimetrically with ammonium ferrothiocyanate (Lasch et al., 2003).  
  
 
2.3 Screening of liposomal formulations for antibacterial activity 
 
A screening test was conducted to investigate which of the 13 formulations yielded 
the highest percent bacterial inhibition. The concentration of each of the suspensions 
was adjusted to the concentration of the formulation with the lowest encapsulation 
efficiency, which was 0.261 mg/ml.   
For the experiments, Staphylococcus aureus was inoculated on nutrient agar plates, 
incubated for 20 h at 37 ºC, and then diluted in PBS to 0.22 OD. Ten microlitres of 
bacterial culture was diluted (1:10) and plated on nutrient agar plates.  CFU counts 
were performed after a 16-hour incubation at 37 ºC.  The final concentration of 
Staphylococcus aureus was then adjusted to 5×105 cfu/ml. 
 
50 µl of the test organism was initially incubated at 37 °C for 20 hours with a 50 µl 
aliquot of each of the 13 formulations in a 96-well microplate, in an orbital shaker 
(Labcon Incubator Labotec (Pty) Ltd, SA). The negative control consisted of 
liposomes encapsulating PBS with 5 % DMSO and the positive control consisted of a 
1 mg/ml solution of amoxicillin in PBS.  Non-encapsulated cyclo(Tyr-Pro) at a 
concentration of 20 mg/ml was also included in the assay.  After incubation, 50 µl of 
MTT dye (0.5 mg/ml) was added to each well.  The plates were again incubated at 
37 °C for 60 minutes to allow for metabolic reduction of MTT.  The plates were 
subsequently removed from the incubator and centrifuged at 3000 rpm (Eppendorf 
5804R, Germany) for 7 minutes to pellet the insoluble formazan precipitate 
(Freimoser et al., 1999).  The supernatant in each of the wells was aspirated and 
discarded.  The formazan product present was dissolved with 100 µl DMSO.  The 
microplates were read at 540 nm using a microplate reader (Biotek Powerwave XS).  
Experiments were conducted in triplicate.  The results are reported (Table 1) as a 
percentage inhibition of growth of Staphylococcus aureus after 20 hours of exposure 
to cyclo(Tyr-Pro) relative to the negative control. 
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2.4 Selection of optimum parameters for liposomal cyclo(Tyr-Pro) formulation 
 
In order to find out the level of each independent variable that would yield a 
liposomal formulation with optimum properties in terms of bacterial inhibition and 
encapsulation against Staphylococcus aureus, a simple search was done within the 
range of the CCD.  This was justifiable because the parameter range of the design is 
selected to include all possible concentrations of the independent variables.  The 
target parameters are listed in Table 2 and Table 3 illustrates the optimised 
formulation as well as the predicted and actual values for the experiments. 
 
2.5 Determination of antibacterial activity of the optimized cyclo(Tyr-Pro) 
formulation 
 
The antibacterial activity of liposome-encapsulated cyclo(Tyr-Pro) was determined, 
in comparison with the free drug against Staphylococcus aureus.  Serial two-fold 
dilutions of the free and liposomal drug were prepared in PBS.  50 µl of each of the 
five cyclo(Tyr-Pro) concentrations were pipette into microplate wells along with 50 µl 
aliquots of the standardised bacterium. The plates were then incubated at 37 ºC for 
20 hours.  Cell viability was quantified using MTT as discussed in Section 2.3. 
  
 
3 Results and discussion 
 
3.1  Particle size and zeta potential 
 
Thirteen liposome suspensions were prepared.  Vesicle size ranged from 149 – 245 
nm and zeta potential –2.47 to -24.1. 
 
 
 
3.2  Regression models of response 
 
Encapsulation efficiency ranged from 2.61 to 5.36 mg/ml and bacterial inhibition from 
14 – 41.3 %.  Runs 2, 3, 8, 9 and 11 were the centre points and were repeated five 
times for estimation of error (Table 1).   
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The computer software, Design Expert 8 was used was for the experimental design 
and regression analysis of the experimental data obtained.  Analysis of variance 
(ANOVA) for the response surface quadratic model is shown in Table 4.  The quality 
of fit of the model equation was expressed by the coefficient of determination R2 
which provides a measure of the proportion of variation (through a regression 
equation), for instance, an R2 value of 0.999 indicates that 99.9 % of the response 
variability can be explained by the model.  Normally, a regression model having an 
R2 value higher than 0.9 is considered to have a high correlation (Li et al., 2007). 
The closer the value of R (correlation coefficient) to 1, the better the correlation 
between the experimental results and the predicted value.   
 
The following equations were derived using Design Expert 8 
 
Y1 = 24.40 + 5.08A + 0.52B – 5.93AB + 5.46A
2 + 9.76B2 
Y2 = 3.55 + 0.54A – 0.40B – 0.95AB + 0.38A
2 + 0.41B2 
These equations are second order response functions representing percent 
encapsulation and percent bacterial inhibition as functions of the two independent 
variables (cholesterol content and phospholipid composition). 
 
3.3  Antibacterial activity of optimised cyclo(Tyr-Pro) formulation against   
Staphylococcus aureus 
The effects of liposomal cyclo(Tyr-Pro) and its free counterpart on the survival rate of 
Staphylococcus aureus, were compared using dose-response curves. A dose-
response curve describes the relationship between response to a drug and the drug 
dose or concentration.  A standard dose-response curve is defined by 4 parameters: 
the baseline response, maximal response or Bmax, the slope of the curve and the 
drug concentration halfway between the baseline and the maximal response, the 
IC50.  The mathematical programme GraphPad Prism version 4 (San Diego, 
California) was used to analyze the effects of increasing drug concentration and 
comparing the effects of the different compounds on bacterial growth.  
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Because the size of formulation 1 was completely out of range compared with the 
other formulations, this formulation was left out of the study.  Encapsulation 
efficiency is defined as the ratio of the amount of active compound remaining in the 
liposome relative to the amount introduced.  It is influenced by a number of factors, 
namely, vesicle type, pH, method of preparation, liposome composition, the ratio of 
lipid to drug and the physicochemical properties of the liposome (Jia et al., 2008).  
Although the 12 liposome formulations were prepared in an identical way, their 
encapsulation efficiencies, differed significantly.  This was particularly important for 
the centre points which were identical in composition.  These discrepancies may be 
due to differences in rigidity and permeability of the membrane bilayer which is 
strongly dependent on the type and quality of phospholipid and additional bilayer 
lipids used.  Alkyl chain length and degree of unsaturation play a major role, for 
example, an 18-carbon saturated alkyl chain produces rigid bilayers with a low 
permeability at body temperature.  The presence of cholesterol also tends to rigidify 
bilayers (Storm and Crommelin, 1998).  In this study, phospholipids with 16 and 18 
alkyl carbon chains as well as cholesterol were used.  The highest percent 
encapsulation was obtained for the formulation which contained a higher proportion 
of DMPC, a 16-carbon lipid, while the lowest was observed to be the formulation with 
a higher proportion of DSPC, an 18-carbon phospholipid. This trend was also 
observed for antibacterial activity of cyclo(Tyr-Pro), where the highest percent 
inhibition was obtained for a formulation containing a higher proportion of DPMC 
than DSPC.  
 
Reliability and adequacy of the empirical models from the two responses was 
confirmed when the actual values obtained from the experiments were compared to 
the estimated values from the regression models.  Points above the diagonal line 
were those that were over-estimated and vice-versa.  The graphs represented in 
Figures 1 and 2 indicated that the experimental design points were not distributed 
along the diagonal line.  
RSM has the advantage of observing interaction effects among independent 
variables.  Interaction occurs when one factor does not produce the same effect on a 
response at different levels of another factor.  If the lines are parallel, there is no 
interaction. On the contrary, when the lines cross, the factors are interacting 
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(Bradley, 2007). Interaction plots for both encapsulation and bacterial inhibition are 
plotted graphically in Figures 3 and 4. P-values are given in Table 4.  These values 
were used as a tool to check the significance of the coefficients in equations in 
Section 3.2, which in turn were necessary to understand the pattern of mutual 
interactions between the variables.  The smaller the p-values were, the bigger the 
significance of the corresponding coefficient (Li et al., 2007).  It was evident that the 
models were highly insignificant with a model p-value of 0.2031 (P < 5 %), lack-of-fit 
value which was not significant at 0.1392 (P > 5 %) and R2 value of 0.6313 for 
response one (bacterial inhibition), and a model p-value of 0.3465, lack-of-fit p-value 
of 0.0772 and an R2 of 0.5366 for response two (encapsulation).   
   
It was obvious that there were major interactions between the two independent 
variables (AB) and responses 1 and 2.  The non-parallel curves (Figures 3 and 4) 
imply that there was a strong interaction between cholesterol content and 
phospholipid composition. As a result of this strong interaction, the AB term 
appeared as one of the significant terms in equations 1 and 2.  The p-values were 
also an indication of the interaction between the two terms.  It was thus concluded 
that the two factors did not have a linear effect on the responses because the 
observed response did not necessarily increase with increasing levels of each factor.   
 
In order to gain a better understanding of the two variables for optimum liposome 
performance, the models were represented as 3-D surface graphs, and these are 
represented in Figures 5 and 6. Figure 5 illustrates the effects of phospholipid 
composition and cholesterol content on the encapsulation of cyclo(Tyr-Pro).  It was 
observed that high initial cholesterol content with a lower proportion of DMPC 
relative to DSPC in the formulation resulted in a high encapsulation efficiency.  It was 
found that increasing the DMPC component had a negative effect on the 
encapsulation efficiency, evident in the dip of the graph with increasing DMPC 
concentration.    A similar trend was observed in Figure 6, where percent bacterial 
inhibition was higher initially, when the lipid composition contained more DSPC 
relative to DMPC, and high cholesterol content.  Biological activity of liposomes 
containing a higher molar ratio of the low Tc phospholipid (DMPC) and a lower 
cholesterol content (less than 20 %) exhibited better biological activity than those 
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with a lower proportion of the 16-carbon lipid (more DSPC) and a higher cholesterol 
content (more than 40 %).   
When selecting a second-order response surface design for response optimisation, 
we want to select a design that will provide a good-fitting model to the data and 
reliable parameter estimates, which then can be used for precise predictions (Myers 
et al., 2009).  There were significant inconsistencies in the experimental results 
obtained for the centre points of this design, which led to failure of the predicted 
model to fit the experimental results.  The omission of run 1, a factorial point, from 
the experiment may have also contributed to the lack of fit of the experimental data 
to the quadratic model.    A logical approach to this short-coming would have been to 
add more replicates at the centre in an attempt to reduce the total error, or 
alternatively to add more axial points, as the outcome of the model would be 
improved with the addition of more runs.  However, due to time and financial 
constraints, any attempt at these potential solutions was not possible. 
 
Significant inhibition of S. aureus growth by liposome-encapsulated cyclo(Tyr-Pro) 
occurred at concentrations as low as 0.425 mg/ml (Figure 7). Binding maximum or 
Bmax for liposomal cyclo(Tyr-Pro) at this concentration was 78.5 %, compared  47.6 
% obtained for the free compound at a concentration of 20 mg/ml.  At full receptor 
occupancy and at a concentration more than 20-fold that of the encapsulated CDP, 
free cyclo(Tyr-Pro) failed to elicit a maximal response. Free cyclo(Ty-Pro) can thus 
be regarded as a partial agonist as the maximum response provoked was 
remarkably less than that observed with the encapsulated CDP. The antibacterial 
activity of liposome encapsulated cyclo(Tyr-Pro) was clearly superior to that of non-
entrapped CDP.  This was evident in the IC50 value of 1.043 for the encapsulated 
drug, which was twice that of the free compound (1.821).   
Liposome preparations of some drugs have shown a significant increase in the 
efficacy or therapeutic indices in pre-clinical models and in vitro studies when 
compared to their ―free‖ counterparts (Omri et al., 2002; Mugabe et al., 2006).  
Entrapment of antimicrobial agents into liposomes has been shown to enhance their 
therapeutic effectiveness (Beaulac et al., 1996, Omri and Ravaoarinoro, 1996; 
McAllister et al., 1999).   This is because liposomes can interact with target cells in 
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various ways and are therefore able to promote intracellular delivery of drugs that in 
their free form would not be able to enter the cell due to unfavourable 
physicochemical characteristics. Furthermore, liposome-encapsulation of these 
agents protects them from extracellular degradation and promotes their delivery to 
the desired site of action, meaning that lower doses of the desired drug can be 
administered (Momekova et al., 2007). 
 
4. Conclusion 
This study aimed to optimize a liposomal formulation containing cyclo(Tyr-Pro) using 
RSM and CCD, and to test its antibacterial activity against Staphylococcus aureus. 
This was achieved through encapsulating cyclo(Tyr-Pro) into liposome formulations, 
characterising these formulations in terms of encapsulation efficiency and testing 
their antibacterial activity against S. aureus.  The MTT assay was used to determine 
the antibacterial effects of liposomal cyclo(Tyr-Pro) in comparison to that of its free 
counterpart.   
Design Expert 8 was used for the purpose of finding the combination of process 
variables that would yield optimal formulations for each bacterium.  The model 
selected by the software failed to adequately correlate the predicted models to the 
experimental data.  This was attributed to the discrepancies in batch-to-batch 
reproducibility encountered in the production of liposomes. 
On the other hand, the results of this study indicated, clearly, that encapsulating 
cyclo(Tyr-Pro) into liposome formulations enhanced the antibacterial activity of this 
compound.  This was evident in the superior activity of this peptide against S. aureus 
at concentrations more than twenty-fold less than its non-encapsulated counterpart.  
These results are remarkable, considering the widespread resistance problem where 
most health professionals would prefer a novel chemical class with no pre-existing 
potential cross-resistance. 
 
Recommendations  
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A possible solution to the short-coming of the model to adequately correlate the 
predicted and experimental data  would be to add more replicates at the centre in an 
attempt to reduce the total error, or alternatively to add more axial points, as the 
outcome of the model would be improved with the addition of more runs.  It is further 
recommended that the exact site of antibacterial action of cyclo(Tyr-Pro) be 
elucidated in order to rationally enhance the efficacy of CDPs.   Also, some work 
needs to be done to determine the effect of bacterial structure on bacterial liposome 
uptake, in the aim to optimise a single liposomal formulation with a broad spectrum 
of antibacterial activity. 
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Table 1: Central composite design consisting of experiments for the study of two experimental 
factors in actual levels with experimental results 
Run # Phospholid 
(A) (%) 
Cholesterol 
B (%) 
Encapsulation 
Efficiency (%) 
Bacterial 
inhibition (%) 
1 80 30 3.53 26.1 
2 50 30 3.78 23.3 
3 50 30 5.36 23.7 
4 92 30 5.01 41.3 
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5 20 40 4.12 31.7 
6 20 20 3.61 27.7 
7 50 44 2.95 35.7 
8 50 30 4.22 30.7 
9 50 30 2.61 20.3 
10 7.6 30 3.26 14 
11 50 30 4.46 31.6 
12 50 16 3.23 36 
13 80 40 3.53 29.3 
 
Table 2: Optimisation parameters for a liposomal formulation for Staphylococcus aureus 
Name Goal Lower limit Upper limit  Importance 
Phospholipid Is in range 0 100 3 
Cholesterol Is in range 0 50 3 
Encapsulation Maximise 2.61 5.36 3 
MIC Maximise 13.6 48 4 
 
Table 3: Experimental and predicted values for bacterial inhibition and percent encapsulation 
Organism Phospholipid Cholesterol  Inhibition (%) Encapsulation (%) 
(%) (%) Predicted Actual Predicted Actual  
S. aureus 15 50 79.8 80.12 6.5 4.25 
 
Table 4: Analysis of variance for response variables 
Source Bacterial inhibition Percent encapsulation 
Model p-value 0.2031 0.3465 
AB p-value 0.3507 0.0772 
Lack-of-fit 0.1392 0.0983 
R2 0.6313 0.5366 
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Figure 1: Relationship between the predicted and experimental encapsulation values. 
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Figure 2: Relationship between the predicted and experimental values for percent bacterial inhibition 
for Staphylococcus aureus 
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Figure 3: Graphical representation of the effect of phospholipid composition and cholesterol content 
on encapsulation 
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Figure 4: Graphical representation of the effect of phospholipid composition and cholesterol content 
on the inhibition of Staphylococcus aureus growth 
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Figure 5: Response surface plot of the combined effects of phospholipid and cholesterol content on 
encapsulation 
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Figure 6: Response surface plot of the combined effects of phospholipid and cholesterol content on 
the inhibition of Staphylococcus aureus 
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Figure 7: Dose response curve representing percentage inhibition of S. aureus after 24 hours 
exposure to liposomal cyclo(Tyr-Pro) and free cyclo(Tyr-Pro) 
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APPENDIX B 
LIST OF EQUIPMENT 
 
Autoclave   Hirayama Manufacturing Corp, Japan 
Centrifuge   Lasec Hermle 2300, Wehingen, Germany 
    Eppendorf 5804R, Germany 
Spectrophotometer  Lasec Cecil LE 2021, Wehingen, Germany 
HPLC system  LC2020 system, Kyoto, Japan 
HPLC column  Phenomenex Luna C8 
PDA detector  SPD M20A PDA detector, Kyoto, Japan 
Incubator   Labcon Incubator, Labex, Orange/grove 
    Edelstahl Rostfrei, Memmert, NT Laboratory 
Extruder   Avanti Polar Lipids, Alabaster, USA 
Microplate reader  BioTech Powerwave XS 
Zeta potential Zetasizer Nano ZS instrument (Malvern Instruments (Pty) 
Ltd., Worcestershire, UK  
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APPENDIX C 
LIST OF SOLUTIONS 
 
1 mg Amoxicillin solution 
Amoxicillin   5 mg 
DMSO  5 % v/v 
RO water to   5 ml 
 
0.5 mg Chloramphenicol solution 
Chloramphenicol 2.5 mg 
DMSO  5 % v/v 
RO water to   5 ml 
 
Cyclic dipeptide solutions 
Cyclo(Tyr-Pro)              100 mg 
DMSO                             5 % v/v 
Normal saline to              5 ml 
 
Mueller-Hinton Broth 
Mueller-Hinton Broth 32 g 
RO water to   1000 ml 
 
MTT solution for determination of cell viability 
MTT dye   0.5 % (0.1 g) 
RO water to   20 ml     
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Nutrient agar 
Nutrient agar  16 g 
RO water to  1000 ml 
  
Phosphate-buffered saline 
NaCl   8.0 g 
KH2PO4  0.2 g 
KCl   0.2 g 
EDTA   0.2 g 
Na2HPO4.12H2O 1.44 g 
HCl (1 M)  qs 
RO water to   1000 ml 
 
0.9 % Sodium chloride solution 
NaCl                                            9.0 g 
Reverse osmosis water to          1000 ml   
 
Triton-X 100 solution 
Triton–X 100 10 % (1 mg) 
RO water to  10 ml 
 
 
 
 
  
 
  
   
